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Protein Arginine Methyltransferase 6 (PRMT6) is the histone tail writer that
methylates the H3R2 (arginine 2 of histone H3) residue, which counteracts the
activating H3K4me3 mark. PRMT6 has been shown to behave both as
transcriptional co-repressor (i.e. trhrombospondin-1, p21, p53), and co-activator
(nuclear receptors). The co-repressor function of PRMT6 is likely the result of
H3K4me3 antagonism, while the mechanism by which PRMT6 exerts its coactivator function has yet to be elucidated. PRMT6 is over-expressed in several
types of tumors including small cell lung cancer, lymphoma, cervical cancer, bladder
cancer, oligodendroglioma, breast cancer, and osteosarcoma, suggesting an
oncogenic role for this enzyme. Importantly, we have found a positive correlation
between PRMT6 over-expression and H3R2me2a elevation in small cell-lung
cancer tissue arrays.
The aim of this project was to study the consequence of PRMT6 overexpression and the effects of elevated histone arginine methylation at the
organismal level in inducible PRMT6 gain-of-function mouse models. To this
purpose, I generated two different systems. One mouse model is based on an ER*Flag-PRMT6 fusion (under a beta-actin promoter), while the other model is based
on a Cre-inducible system, generated by cloning a floxed transcriptional Stop
cassette upstream a Flag-PRMT6 (under a beta-actin promoter). Upon PRMT6

induction, both mouse models show elevated asymmetric dimethylation of H3R2
compared to wild type mice, demonstrating for the first time that PRMT6 methylates
this residue in vivo. The ER*-PRMT6 mice die upon stabilization of the chimera and
serum analyses have revealed elevation of Interleukin 6 (IL-6) levels, a key
interleukin regulated by the transcription factor NF-B. This finding has led us to the
discovery that PRMT6 functions as a co-activator for NF-B. I have found that
PRMT6 is in the NF-B complex, and that its overexpression enhances NF-B
transcriptional activity in luciferase assays and quantitative Real-Time PCR
experiments. The activity of PRMT6 is clearly necessary for the coactivator function.
ChIP analysis demonstrated that PRMT6 was recruited to the IL-6 promoter upon
TNF-alpha stimulation. Moreover overexpression of PRMT6 caused RelA shuttling
into the nucleus in our system, which could justify, at least in part, the mechanism
underlying the coactivator function. I have also found that PRMT6 can deposit the
H4R3me2a activating mark in vivo, which could explain the co-activator role of this
arginine methyltransferase.
The Cre-inducible PRMT6 transgenic mice have been crossed with a mouse
line expressing a Cre recombinase under a Keratin 5 (K5) promoter, as well as with
a MMTV-Cre mouse line. I have conducted carcinogenesis studies with these mice.
The K5-Cre crossed mice have been subjected to skin carcinogenesis study using
the DMBA/TPA system and to a p53+/- genetic cross. The MMTV-cre crossed mice
have been subjected to ageing studies. I have also performed RNA-seq
experiments on primary mammary epithelial cells from the MMTV-Cre crossed mice.

In conclusion, this work identifies PRMT6 as a novel regulator of the
inflammatory process, indeed we found that it cooperates with the transcription
factor NF-B in activating early response inflammatory genes such as IL-6 and TNFalpha.
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Chapter 1
Introduction
1.1 Arginine methylation
Arginine methylation is an important post-translational modification catalyzed by the
protein arginine N-methyltransferase (PRMT) family of enzymes, composed by nine
members. Arginine methylatilation is involved in a many cellular processes, like
transcription, RNA metabolism, and DNA damage repair (1). Arginine residues can
be methylated in three different modes on the guanidino group: monomethylated
(MMA), symmetrically dimethylated (sDMA) and asymmetrically dimethylated
(aDMA), and each of these methylated states can result in different biological
outcomes (Figure 1). There are nine PRMTs – type I and type II enzymes (PRMT1,
2, 3, 4, 6 and 8) catalyze the formation of a MMA, type I PRMTs further catalyze
aDMA formation, while type II PRMTs (PRMT5) catalyze the formation of sDMA.
PRMT7 is a type III enzyme that predominantly catalyzes MMA, and the PRMT9 has
yet to be characterized (Figure 2). Arginine methylation constitutes a signal to recall
readers of the histone code. This recognition event is fundamental in order for
specific biological outcomes to happen. For example, methylation of SmB by
PRMT5 is required for an interaction with the Tudor domains of SMN and TDRD3
(2), methylation of CA150 by CARM1 also provides a docking site for SMN (3), and
H3R17 methylation by CARM1 promotes TDRD3 binding (4). Thus, motifs harboring
either aDMA or sDMA residues bind a subset of Tudor domain-containing proteins.
An aromatic “cage” in the Tudor domain forms the methyl-binding pocket (5).
Arginine methylation can also block protein-protein interactions. For example, the
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methylation of arginine residues in the vicinity of proline-rich motif can block the
binding to Src homology 3 (SH3) domains (6). Another example of arginine
methylation blocking a protein-protein interaction is the CARM1-modified-GRIP1
binding domain of p300 (5). Finally, the methylation of histone H3R2 (by PRMT6)
antagonizes the binding of effector proteins to the N-terminal tail of H3, thus serving
as a repressive mark that counteracts the activa H3K4me3 mark (7-9).

2

Figure 1. Types of Methylation on Arginine Residues.
From Bedford and Clarke, 2009 (1).
Copyright License number 3324800889013 (Molecular Cell).

3

Figure 2. The Protein Arginine Methyltransferase Family. The mammalian PRMT family
currently contains nine highly related members; all harbor signature motifs I, post-I, II, and III
and the conserved THW loop (in black bars). Protein domains that might assist in substrate
recognition are marked in gray boxes.
From Bedford and Clarke, 2009 (1).
Copyright License number 3324800889013 (Molecular Cell).
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1.2 PRMT6
PRMT6 is an enzyme with auto-methylation capabilities that localized strongly in the
cell nucleus (10). Substrates for this PRMT include the nuclear scaffold protein
HMGA1a/b (11,12), DNA polymerase beta, and the HIV Tat protein (13,14). PRMT6
has also shown to impact the histone code, indeed it is the primary enzyme
responsible for H3R2 methylation in mammalian cells (7-9). PRMT6 can strongly
methylate H3K4me1 and H3K4me2 peptides, and weakly methylate a H3K4me3
peptide (7). However, prior methylation of the H3R2 site prevents the MLL1 complex
from methylating H3K4 (9). H3K4 methylation is found in promoters of active genes
and recalls chromatin-remodeling enzymes that open chromatin for transcription.
The effector molecules that recognize H3K4me3 possess methyl-specific binding
domains, like PHD, Chromo and Tudor domains. H3R2 methylation blocks the
capability of many specific domains to bind to H3K4me3 in in vitro assays (7).
Therefore

PRMT6, by generating the H3R2me2a mark, functions as a

transcriptional repressor because this mark impedes recruitment of remodelers to
the H3K4me3 mark (Figure 3). In a massive qChIP study to identify the histone
marks that are present on chromatin prior to Myc binding, it was found that
H3R2me2a (the PRMT6 mark) is associated with the repressive H3K27me3 mark
(deposited by EZH2) and low-affinity Myc binding site (15). Related studies by the
same group found a negative correlation between H3R2me2a and H3K4me3, and a
negative correlation between H3R2me2a promoter methylation and transcription (8).
This finding supports the proposed role of PRMT6 in transcriptional repression and
implicated this PRMT in the regulation of Myc recruitment and binding to chromatin.
In yeast, the H3R2me2a mark has also been associated with transcriptional
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repression, although the yeast enzyme that deposits this mark has not yet been
identified (16,17). The tumor suppressors p21, p27 and p53 have been recently
reported to be directly repressed by PRMT6 through deposition of the repressive
H3R2me2a mark in their promoters (18-21).

PRMT6 also deposits the

H2AR29me2a mark, which is enriched at the promoters of genes that are
transcriptionally repressed by PRMT6 (22).
The assumption that PRMT6 is a transcriptional repressor has recently been
challenged by finding it functioning as SHR coactivator: Its mode of action is similar
to that of PRMT1 and CARM1, indeed it functions as a secondary coactivator to
p160/SRC proteins. PRMT6 binds to SRC-1, and acts synergistically with SRC-1 to
coactivate ERα (23), but the mechanism for this coactivator function is yet to be
elucidated. PRMT6 also methylates the N-terminal tails of histones H4 and H2A
(their first 5 residues are the same) at R3 in in vitro reactions (9); however the
methylation of these sites is yet to be shown in vivo. The H4R3me2a is known to be
associated with actively transcribed gene promoters, and it is deposited primarily by
PRMT1 in vivo (24). In the coactivation context, methylation of H4R3 and/or other
active sites may be important. Indeed, PRMT6 has recently been reported to
methylate H3R42 and that this non-tail histone methylation event positively affects
transcription, likely by disrupting the histone-DNA interaction and making the
nucleosome slidable (25).

6

Figure 3. The site of PRMT6-mediated methylation on the H3 histone tail is noted. The wellcharacterized CARM1 methylation sites, which are associated with transcriptional activation,
are also indicated. H3R2 methylation structurally impedes the binding of H3K4me3 recognition
domains and also prevents H3K4 methylation by the MLL1 complex. H3R2 methylation
antagonizes the docking of a number of H3K4me3 effector proteins. PRMT6 thus functions as
a general transcriptional repressor by blocking the activator functions H3K4me3. From
Bedford and Clarke, 2009 (1).
Copyright License number 3324800889013 (Molecular Cell).
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1.3 PRMTs and Nuclear Factor Kappa B (NF-B)
Nuclear factor Kappa B (NF-B) is an inducible transcriptional factor that plays a
pivotal role in immune system regulation, cell survival, differentiation and
proliferation (26). Dis-regulation of NF-B has been associated with numerous
diseases, including malignancies in which it is intrinsically activated, resulting in
tumor survival by enhancing transcription of proliferative and anti-apoptotic genes
(27). Five NF-B family members in mammals have been described: RelA/p65,
RelB, c-Rel, p50 (NF-B 1), and p52 (NF-B 2). The N-termini of NF-B factors
harbor a conserved region of 300 amino-acids, called Rel homology domain (RHD).
Of the five members described, only p65, c-Rel, and RelB have C-terminal
transactivation domains (TADs), which function to activate transcription (28). NF-B
proteins bind either as homodimers or heterodimers to the target DNA RelA(p65)/p50 dimer is the most abundant and well studied NF-B form. NF-B
dimers are retained in the cytoplasm in normal conditions by association with the
inhibitory IB proteins. Extracellular stimuli such as cytokines (i.e. tumor necrosis
factor alpha (TNF-alpha)), bacterial lipopolysaccharide (LPS), and others activate
phosphorylation cascades that result in phosphorylation, ubiquitination, and
proteasomal degradation of IB proteins, with consequent translocation of NF-B
dimer into the nucleus and transcription of target genes (29,30). Intracellular
responses to DNA damage and reactive oxygen species can also activate NF-B
(26). NF-B-dependent gene transcription requires multiple co-activators that
function by bridging it to the basal transcription machinery and altering chromatin
structure (31). The co-activators histone acethyl-tansferases p300 and its homolog,
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the CREB-1-Binding Protein (CBP), are known to impact NF-B-dependent gene
expression and have been shown to interact directly with RelA. Moreover NF-Bdependent gene expression involves another class of transcriptional coactivators,
such as steroid receptor-coactivator-1 (SRC-1), which interacts with the p50 subunit
of NF-B to potentiate transactivation (32). In Figure 4 is shown the complex
(Enhanceosome) that forms at IL-6 promoter one of the NF-B target genes (33).
Members of the protein arginine methyltransferase family (PRMTs), namely PRMT1
and PRMT4/CARM1, well known as steroid hormone receptor (SHR) coactivators
(34,35), have also been shown to cooperate in NF-B-dependent gene activation.
CARM1 has been shown to function as promoter-specific coactivator for NF-B in
concert with p300/CBP and SRC-2/TIF2/GRIP1 through deposition of the
H3R17me2a active mark at NF-B-regulated promoters (36,37). PRMT1 has been
reported to coactivate NF-B-dependent gene expression synergistically with
CARM1 and PC1/poly(ADP-ribose) polymerase 1 (PARP1) (38).
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Figure 4. Overview of the phosphorylation pathways leading to activation of the IL-6 enhanceosome. The
expression of IL-6 needs to be very strictly regulated and the IL-6 gene promoter contains a plethora of
sequence elements, which can be triggered via different activation schemes. Induction of IL-6 by the
inflammatory cytokine TNF is exclusively mediated by the stress-responsive transcription factor NF-kB.
However, other DNA-bound transcription factors also contribute to the general level of expression and help to
establish a multi-protein complex, a so-called ‘enhanceosome’, at the promoter DNA. Herein, NF-kB serves as
the ultimate trigger to turn this enhanceosome into a fully transcriptionally competent complex, which is capable
of gene induction. (Ac, acetyl; AP-1, activator protein-1; BTM, basal transcription machinery; C/EBP, CCAAT
enhancer-binding protein; CREB, cAMP-responsive element binding protein; p/CAF, p300/CBP-associated
factor; Pol, polymerase; SRC, steroid receptor activator.
Suorce: (33). Copyright License number 3324800111184 (the EMBO Journal).
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1.4 PRMTs, PRMT6 and Cancer
PRMTs have been shown to impact numerous cellular processes, including
proliferation, transformation and the anti-apoptotic pathway, therefore they may play
an important role in tumorigenesis (39). PRMT1 mRNA levels have been reported to
be higher in breast cancer cell lines than in controls (40). In addition, PRMT1 plays
a role in the transforming abilities of the MLL-EEN gene fusion product (41). CARM1
levels are elevated in castration-resistant prostate cancer, as well as in aggressive
breast tumors (42,43). Importantly, CARM1 methylates AIB1, thereby regulating its
activity and stability (44,45). CARM1 is recruited to ER regulated promoters by
AIB1, and it is essential for estrogen-induced proliferation of the MCF-7 breast
cancer cell line (46). Moreover, while this thesis was being written, a publication
showed that CARM1 methylates the chromatin remodeling factor BAF155 to
enhance tumor progression and metastasis (47). PRMT5 is recruited by SNAIL to
actively repress E-cadherin expression (48). A hallmark of epithelial-mesenchymal
transition (EMT) is the loss of E-cadherin expression, which plays an important role
in tumor progression. PRMT5 overexpression promotes anchorage-independent cell
growth (49), supporting the notion that PRMT5 might be an oncoprotein. Consistent
with this idea, PRMT5 levels are elevated in gastric cancer (50) and in leukemia
cells (51). Microarray analysis of PRMT6 knockdown cells revealed that
thrombospondin-1 (TSP-1) is transcriptionally repressed by this PRMT (52). TSP-1
is a potent natural inhibitor of angiogenesis, and reduction of its levels have been
shown to promote tumor progression. The HOXA10 gene is strongly regulated
(repressed) by PRMT6 activity (9). HOXA10 is a positive regulator of the p53 tumor
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suppressor gene (53). Thus, increased PRMT6 levels will result in decreased
HOXA10 levels and consequently attenuated p53 function. Moreover, as already
mentioned, the tumor suppressors p21, p27 and p53 have been recently reported to
be directly repressed by PRMT6 through deposition of the repressive H3R2me2a
mark in their promoters (18-21).
As already mentioned, PRMT6 generates the H3R2me2a mark, and the majority
of H3K4me3 effector molecules are sensitive to H3R2me2a methylation (7). A key
group of these H3K4me3 readers that are blocked from binding are the ING family
of PHD domain-containing proteins. ING proteins are down-regulated in a broad
variety of cancer types and are regarded as tumor suppressors (54). Elevated
PRMT6 levels result in increased H3R2me2a methylation, which in turn will
effectively incapacitate ING protein effector functions. A search of the Oncomine
transcriptome database (www.oncomine.org) confirmed that indeed PRMT6 is overexpressed in a number of tumors, including SCL, cervical cancer (Figure 5A), as
well as acute lymphoblastic leukemia and others (data not shown). In addition,
PRMT6 expression levels correlate with poor prognosis in oligodendroglioma
patients (Figure 5B). To confirm this observation at the protein level, we obtained
small cell lung carcinoma tissue microarrays from Folio Biosciences, which had 33
carcinomas and 5 normal samples arrayed. These arrays were probed for both
PRMT6 and for the mark that it deposits, H3R2me2a (Figure 5C). In the normal
lung tissue, PRMT6 levels were mostly below the level of detection (although there
was strong non-specific cytoplasmic staining in a subpopulation of cells, apparently
of secretory material). All tumors had nuclear PRMT6 staining not seen in normal
bronchial epithelium. The average % positive nuclei was 12.6% (range, 2.8-36.3%)
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for PRMT6. In control bronchial epithelium, 5.9% cells had nuclear staining for
H3R2me2a. Ninety-four percent (31/33) of tumors analyzed had higher proportions
of H3R2me2a-positive nuclei than control tissue. On average, the percentage of
positive nuclei in tumor cells (mean, 35.5%; range, 0.6-82.6%) was six-fold the
percentage in control tissue and, overall, the H3R2me2a staining intensity was
greater in tumor nuclei compared to non-neoplastic cell nuclei. Nuclear staining for
H3R2me2a and PRMT6 was evaluated on slides scanned by an Aperio ScanScope
using ImageMate software. An average of 14,000 tumor cells per sample were
evaluated. Control tissue was bronchial epithelium from adjacent normal tissue,
where small cell carcinomas of the lung are believed to arise. Altogether, 2,600
control cells were evaluated.
The H3R2me2a mark is deposited by PRMT6. Thus, tumor samples that
overexpress PRMT6 should also display elevated levels of H3R2me2a. To establish
if there is such a positive correlation between PRMT6 and H3R2me2a levels, paired
analyses were obtained for 33 tumor samples and results were expressed as
percentage immunopositive nuclei. Linear regression analysis was performed to
determine if there was a relationship between PRMT6 and H3R2me2a staining
(Figure 5D). A least squares rho value of 0.806 was obtained, with an F-test value
of 9.2994. This indicates that PRMT6 values can explain approximately 80% of the
variance in H3R2me2a values. An F value of greater than 4 is considered
statistically significant. Thus, there is a positive correlation between PRMT6 and
H3R2me2a staining.
A detailed analysis of PRMT6 (and PRMT1) deregulated expression in different
human cancers was performed. This study reported that PRMT6 is overexpressed
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in a number of human cancers, including bladder, small cell lung carcinomas,
lymphomas, breast cancer, and cervical cancer (55) (Figure 5E). Recently, PRMT6
has also been found to be dramatically elevated in prostate carcinomas (56).
Thus, three separate lines of evidence support the fact that PRMT6 levels are
significantly elevated in tumors: 1) Oncomine data, 2) tissue microarray analysis
performed by us, and 3) a thorough analysis of PRMT6 levels in a large number of
different tumors performed by the group of Hamamoto and a recent paper from the
group of Jeronimo (55,56). Importantly, although there are numerous in vitro studies
linking aberrant PRMT function to cancer, no mouse models have been developed
to address this issue.

14

Figure 5. PRMT6 levels are elevated in tumors. (A) Analysis of the Oncomine database reveals
that PRMT6 is significantly overexpressed in SCLC and cervical cancer. (B) PRMT6 expression
levels correlate with poor prognosis in oligodendroglioma patients. (C) Tissue microarray analysis
of PRMT6 and H3R2me2a in small cell lung carcinomas. Top two panels represent adjacent
normal tissue. The other six panels represent three of the 33 carcinoma cores, stained for both
PRMT6 and H3R2me2a. Pictures were taken by Donna Kusewitt. (D) Linear regression analysis
was performed on the levels of PRMT6 and H3R2me2a in each sample; their expression levels
strongly correlate. E, PRMT6 levels are elevated in a number of different tumors. The data is
presented as a signal intensity ratio (Tumor/Normal). The data in (E) was published data adapted
from Yoshimatsu et. al. 2011 (55).
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1.5 DMBA/TPA skin carcinogenesis
The two stage skin carcinogenesis system that employs the tumor initiator agent
DMBA (7,12-dimethylbenz[a]anthracene) and the tumor promoter TPA (Otetradecanoyphorbol-13-acetate) has been largely employed to address of a number
of questions about the fundamental biology of epithelial cancers (57). In this
protocol, by administering a single dose of DMBA followed by repeated applications
of TPA, mice develop initially primarily papillomas, which progress to Squamous
Cell Carcinomas (SCCs) that are histologically very similar to human SCCs. In
accordance with the cancer stem cells hypothesis for cancer development, the
mechanism for tumor initiation in DMBA/TPA two-stage carcinogenesis protocols
involves mutation in the critical target Ha-ras gene of stem cells. These cells are
found in the bulge region of hair follicles or basal compartment of interfollicular
epidermis in mice (57). The gene targets for initiation by chemicals in mouse skin
resemble those found in other human epithelial cancers (e.g., lung, colon, and
pancreatic cancers) (58). The tumor promoter TPA will affect gene expression, and
stimulate epidermal cell proliferation. The progression of papillomas to SCC does
not depend on the tumor promoter agent TPA, it rather occur stochastically following
numerous gene expression changes (59,60).

1.6 Innovation of this study
The innovation of this project lies in the novel and sophisticated mouse models,
which allow for the conditional and inducible modulation of PRMT6 activity to study
the role of this PRMT in biological processes, such as cancer. There is evidence
gleaned from in vitro experiments that PRMT6 functions as both a transcriptional
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repressor and activator. In this study I sought to determine the biological relevance
of these findings in an in vivo setting by investigating the transcriptional
repressor/activator functions of PRMT6 in gain-of-function mouse models. This
study is highly relevant due to the recent observations that PRMT6 is up-regulated
in a number of tumors, including SCLC, lymphomas and cervical cancer (Figure 5).
I have exploited novel mouse models to understand the role of PRMT6 in cancer
development using state-of-the-art approaches.
Epimutations, unlike genetic mutations, can be reversed by chemotherapeutic
intervention, which makes epigenetic therapy conceptually extremely appealing.
Drug therapies that target chromatin have been touted as the next emerging frontier
for the treatment of cancer. Epigenetic drugs are currently being used in the clinic.
Clearly, dramatic changes in epigenetic patterns and gene transcription are major
signatures of cancer and PRMT6 may play a significant role in this reprogramming.
The reversal of these aberrant patterns is emerging as a therapeutic strategy for the
treatment of cancer.
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Chapter 2
Rationale, Hypothesis and Specific aims
Rationale
PRMT6 is an arginine methyltransferase that was first identified and described by
our group. PRMT6 has been reported to be the predominant enzyme to methylate
the H3R2 (arginine 2 of histone H3) residue. The proximity of this arginine residue to
the H3K4me3 activation mark raises the possibility of crosstalk between these two
methylation events. PRMT6 likely functions as a transcriptional repressor in two
ways: 1) by blocking the recruitment of transcriptional activators to the methylated
H3K4 mark and 2) by preventing H3K4 methylation by MLL1. On the other hand,
PRMT6 has recently been described as co-activator for nuclear receptors by the
Dowhan’s group, although the mechanism for this coactivation was not described in
the manuscript. A likely mechanism by which PRMT6 will function as a coactivator
has recently come to light with the finding that it methylates a site in the core of
histone H3, H3R42me2a and that this non-tail histone methylation event positively
affects transcription, possibly by disrupting the histone-DNA interaction and making
the nucleosome “slidable”. Moreover, PRMT6 has been shown to generate the
active H4R3me2a mark in in vitro reactions, however this methylation event is yet to
be shown in vivo. The ability of transcription factors and transcriptional regulators to
function as both activators and repressors in a context dependent manner is not
novel, and well-characterized examples include p53, myc, E2Fs, LSD1 and TRIM24.
Importantly, PRMT6 is over-expressed in several types of tumors including
small

cell

lung

cancer,

lymphoma,

cervical

cancer,

bladder

cancer,
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oligodendroglioma, breast cancer, and osteosarcoma, suggesting an oncogenic role
for this enzyme. Notably, we have found a positive correlation between PRMT6
over-expression and H3R2me2a elevation in small cell-lung cancer tissue arrays.
We would like to understand the consequence of altered PRMT6 expression at the
organismal level.

Hypothesis
We hypothesized that PRMT6 is a major transcriptional regulator may contribute to
cancer susceptibility. To explore the potential roles of PRMT6 in cancer
development, we generated two PRMT6 gain-of-function mouse models.

Specific Aim 1 - Generation and characterization of two types of PRMT6 gainof-function mouse models.
Transgenic mouse lines over-expressing an ER*-Flag-PRMT6 chimera were
generated. In order to produce these mice an ER*-Flag-PRMT6 sequence was
cloned in the pCAGGS vector and the construct was employed for pronuclear
injection, generating ER*-PRMT6 lines. As an alternative approach, we generated a
transgenic mouse model based on a Cre-inducible system. For this second model, a
transcriptional stop cassette was cloned upstream a Flag-PRMT6 in a pCAGGS
vector and the construct was employed to produce transgenic mouse lines. These
lines (called STOP-PRMT6) were crossed with mice expressing a Cre recombinase
under a Keratin 5 promoter (K5-Cre mice) as well as with mice expressing a Cre
recombinase under a MMTV promoter (MMTV-Cre mice).
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Specific Aim 2 - To determine the impact of PRMT6 over-expression on skin
carcinogenesis.
A chemical skin carcinogenesis experiment was set-up with STOP-PRMT6 mice
(crossed to the K5-Cre mouse line) employing the tumor initiator agent DMBA and
the promoter TPA. A number of endpoints were compared between the control and
experimental group, including tumor incidence, latency, multiplicity, and malignancy.

Specific Aim 3 - To determine if increased PRMT6 activity cooperates with p53
deficiency in tumor development.
Mice heterozygous for p53 are prone to develop tumors by loss of the intact p53
allele. The STOP-PRMT6/K5-Cre mice were crossed onto a p53+/- background to
determine if increased PRMT6 activity cooperates with tumor development through
epigenetic silencing of he p53 WT allele.

Specific Aim 4 - To determine the impact of PRMT6 overexpression on the
mammary gland.
In order to investigate the impact of PRMT6 over-expression on the mammary gland
we crossed the STOP-PRMT6 mice with a MMTV-Cre mouse line and characterized
them. The bigenic mice STOP-PRMT6/MMTV-Cre showed increased proliferation
in the mammary gland epithelium, therefore we set-up ageing studies in order to
explore the possibility of increased mammary tumorigenicity. We also performed a
RNA-Seq experiment using primary mammary epithelial cells (organoids) isolated
from the bigenic STOP-PRMT6/MMTV-Cre mice, along with 2 control groups
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(STOP-PRMT6 and MMTV-Cre), in order to investigate the impact of PRMT6
overexpression on the mammary transcriptome.
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Chapter 3
Materials and Methods

Antibodies, cells and reagents
HEK 293 and HeLa cells were purchased from ATCC and cultured in Dulbecco’s
Modified Eagle Medium (DMEM) containing pen strep, non-essential amino-acids
and FBS 10%. Tamoxifen (cat. # T5648), OHT (cat. # H7904) and TNF-alpha (cat. #
T6674) were purchased from Sigma. Anti-RelA antibody for WB and IF was from
Abcam (cat. # ab16502). Anti-hPRMT6 antibody was from Imgenex (cat. # IMG506). Anti-PRMT6 atibody (for mouse and human) was from Bethyl Laboratories
(cat. # A300-929A). Anti-Flag antibody (cat. # F3165) and anti-Flag agarose (cat. #
A2220) were obtained from Sigma. Anti-H3R2me2a antibody was from Millipore
(cat. # 05-808). Anti-GFP antibody was from Life Technologies (cat. # A6455). AntiLamin A/C antibody was from Santa Cruz (cat. # sc-20681). Anti- H4R3me2a was
from Active Motif (cat. # 39705). Protein A/G Ultra Link resin was from Thermo
Scientific (cat. # 53132).

DMBA was purchase from Sigma, TPA was from LC

Laboratories (cat # P-1680).

Transgene construction and mouse generation
Estrogen receptor hormone-binding domain variant (ER*) that bind Tamox, but not
estrogen, was a gift from Martin McMahon (61). ER* was generated by PCR (from
the pBP3hbER* vector) and cloned into a pCAGGS construct containing flagged
human PRMT6 cDNA. For the Cre-inducible construct, a Stop cassette was
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amplified by PCR from the RAGE vector, previously described (62) and cloned into
a pCAGGS construct containing flagged human PRMT6 cDNA. In both cases, an
aliquot of the construct produced by Midi Prep using Qiagen kit (Qiagen Scientifics,
Maryland) was linearized overnight using ScaI, then column purified using PCR
purification kit from Qiagen (Qiagen Scientifics, Maryland). This transgene was
injected into the male pronucleus of day 1–fertilized (FVB) embryos. Injected
embryos were transferred into day 1–plugged pseudo-pregnant foster mice, and
litters were screened for the presence of the transgene using Southern analysis to
identify heterozygous founders. Founder mice were backcrossed to establish lines
of animals.

Southern genotyping
Approximately 1000 bp of PRMT6 cDNA sequence was cloned out from a
pCAGGS-Flag-PRMT6 construct to use as a template for probe generation by PCR
using the primers Forward 5’-ATGGACTACAAGGACGACGATGACAA-3’ and
Reverse

5’-GATAGGCAGCCTGCACCTGAGGAGTG-3’.

The

radiolabeled

hybridization probe was prepared with 32P-dCTP using the Random Primer Labeling
kit from Agilent Technologies (cat. # 300385), following manufacturer’s instructions.
Genomic DNA was isolated from the tails of 3-week old mice and digested EcoRI
enzyme. Digested DNA was run on 1% agarose gel overnight and transferred to a
nitrocellulose membrane. The membrane was then cross-linked and incubated in 10
mL Southern hybridization buffer containing SDS, the radioactive probe and salmon
sperm DNA overnight at 42° C, then washed with SSC buffer (3.0 mol /L NaCl, 0.3
mol /L sodium citrate) and exposed to film for 1–3 days at –80° C.
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Administration of tamoxifen to mice
To activate ER*-PRMT6 in adult transgenic mice by Tamox topical administration,
Tamox was

and applied topically to a shaved

area of dorsal skin. As control, WT littermates treated with Tamox or transgenic
littermates treated with ethanol, were included in these studies. For intraperitoneal

Stable cell line generation
HEK 293 cells were transfected with the pCAGGS-ER*-PRMT6 construct (10 g)
along with an empty plasmid carrying neomycin resistance (1g). Selection of stable
transfected cells was performed using neomycin (G418).

Immuno-staining of mouse tissue and immuno-fluorescence HeLa cells
Tissue samples were obtained from WT or transgenic mice, Tamox or vehicle
treated. Tissues were fixed overnight in neutral buffered formalin (24 hrs),
transferred to 70% ethanol, then embedded in paraffin and sectioned (5 μm). Slides
were de-paraffinized with standard procedure. For immunohistochemistry (IHC),
non-specific antibody binding was blocked by incubating slides with Biocare
Blocking Reagent (cat# BS966M) for 10 minutes. Slides were drained and incubated
with primary anti-Flag antibody for 30 minutes at room temperature, then washed
with PBS and incubated with biotinylated rabbit-anti-mouse secondary antibody for
15 minutes at room temperature. After washing, slides were incubated with SA-
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HRP (Biocare) for 30 minutes at room temperature, washed again and incubated
with BioGenex DAB monitoring staining development. Slides were then washed,
counterstained, dehydrated and mounted. For immunofluorescence (IF), after
deparaffinization slides were blocked with 20% FBS 30 minutes, washed and
incubated with primary antibody for 1hr, then secondary antibody Texas Redconjugated, followed by DAPI staining. In the case of HeLa cells, cells were grown
on a coverslip to 70% confluency and transfected with GFP or GFP-PRMT6 for 24
hrs. Cells were then rinsed with PBS and fixed with 4% paraformaldehyde for 15
min at room temperature. Cells were washed with washing solution (0.1% NP-40 in
PBS), blocked in 20% FBS, incubated with primary antibody anti-RelA (in washing
solution) 1 hr at room temperature, washed 3 times incubated with secondary
antibody Alexa Fluor 555-conjugated 30 minutes, and DAPI stained afterwards.

Isolation of mouse embryonic fibroblasts
Briefly, a 12.5-day plugged mouse was sacrificed following standard procedure.
Intact embryos were collected and placed in 6-well plates containing 3 mL DMEM
10% FBS and pen-strep. Embryos were mechanically disrupted passing them
through a 5 mL syringe with a 18G needle 5 times, then plated in 10 cm dish
containing 10 mL of media. Media was changed every day for 3 days.

Western Blotting (WB) and co-immunoprecipitation (co-IP)
For total cell lysates, cultured cells (80% confluency) were scraped from a tissue
culture dish, lysed in RIPA buffer containing protease inhibitor cocktail and
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denatured by boiling. In the case of cell fractionation, the NE-PER kit from Thermo
Scientific (cat. # 78835) was employed. For tissue lysates, tissues were harvested,
snap frozen in liquid nitrogen, grounded using a mortar, transferred in RIPA buffer
with protease inhibitors and sonicated 3 times using Fisher Scientific Sonicator
Model 500 (25% power, 10 sec each cycle). Protein lysates (30-50 g) were
resolved on SDS-PAGE gel. For the co-IPs cells were lysed in a mild co-IP buffer
[50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM
EGTA, 15 mM MgCl2] containing protease inhibitor cocktail and incubated with
primary antibody anti-GFP or with anti-flag agarose O/N at 4 °C. In the case of antiGFP IP, lysates were incubated with protein A/G agarose the next day for 3hrs at
4°C, then the agarose was washed in co-IP buffer 3 times, denatured by boiling and
resolved on SDS-PAGE gel. In the case of anti-Flag agarose, we proceeded with
washing the beads extensively, boiling and resolution on SDS-PAGE gel. The
resolved proteins were transferred on PVDF membrane, incubated in 5% non-fat
milk 30 min at RT, and subsequently incubated with specific primary antibody in
non-fat milk overnight at 4 °C. The s were washed three times in PBS containing
0.2% Tween-20 and incubated for 1 hr in peroxidase-conjugated IgG diluted 1/5000
in non-fat milk at RT. s were washed and immune complexes detected with ECL.

Acid extraction of histones
For histone purification, cells were first fractionated using NE-PER kit from Thermo
Scientific (cat. # 78835). After isolating the nuclear fractoion, 150 L of 0.8 M HCl
was added to the chromatin pellet and sonication at 30% power using Fisher
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Scientific Sonicator Model 500 (15 seconds) was performed. Samples were then
centrifuged, and the supernatant neutralized adding Tris–HCl 1.5M, pH 8.5 (90 L)
and loaded on SDS-PAGE gel for quantification by coomassie staining.

Chromatin immunoprecipitation (ChIP)
HeLa cells at 80% confluency were transfected with 10 μg of a FLAG-PRMT6
vector. 24 h after transfection, cells were treated with TNF-alpha or PBS (vehicle).
ChIP analysis was performed using the Millipore Magna ChIP assay kit protocol
(cat# 17-610). For the immunoprecipitation, 2 μg of PRMT6 antibody was used for
each condition and incubated overnight at 4°C. Quantitative Real time-PCR was
performed with the Applied Biosystems 7900HT real-time PCR instrument using the
iTaq Universal SYBR Green Supermix form Bio-Rad (cat. # 172-5121).
The primer sequences were as follows:
8000 upstream TSS:
For. 5’- GCTCCTCCATCTGGTGTCAT-3’, Rev.5’-AAATTGGGGGTAGGGTTGTC-3’
IL-6 TSS:
For. 5’-AATGTGGGATTTTCCCATGA -3’,Rev. 5’-AGTTCATAGCTGGGCTCCTG -3’

RNA isolation and quantitative real-time PCR
RNA was isolated from 80% confluent cell plates using TRIzol Reagent (Invitrogen,
Carlsbad, CA). cDNA was prepared from total RNA (1g) using the Superscript III
First Strand Synthesis System for RT-PCR from Invitrogen (cat. # 18080-051)
following the manufacturer's protocol. Quantitative Real time-PCR was performed
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with the Applied Biosystems 7900HT real-time PCR instrument using the iTaq
Universal SYBR Green Supermix form Bio-Rad (cat. # 172-5121) with primers for
the indicated genes. Primers were designed across exons.
The primer sequences were as follows:
IL-6:
For. 5’-ACTCACCTCTTCAGAACGAATTG-3’, Rev.5’-CCATCTTTGGAAGGTTCAGGTTG-3’
TNF-alpha:
For. 5’-CCCCAGGGACCTCTCTCTAA-3’, Rev. 5’-TGAGGTACAGGCCCTCTGAT3’
MCP1/CCL2:
For. 5’-TCTGTGCCTGCTGCTCATAG-3’, Rev. 5’-GCTTCTTTGGGACACTTGCT-3’
COX-2:
For. 5’- TGAAACCCACTCCAAACACA-3’, Rev. 5’-GAGAAGGCTTCCCAGCTTTT-3’
IKB-alpha:
For. 5’-AGACCTGGCCTTCCTCAACT-3’, Rev. 5’-TGCTCACAGGCAAGGTGTAG3’
GAPDH:
For. 5’-AGCCACATCGCTCAGACAC-3’, Rev. 5’-GCCCAATACGACCAAATCC-3’

Luciferase reporter assay
HEK 293 cells were cultured in 10% FBS supplemented DMEM in 24-well plates to
70% confluency. For reporter gene assays, cells were co-transfected with 200 ng of
the NF-B luciferase reporter plasmid, 25 ng Renilla control luciferase plasmid (pRL)
and the indicated constructs (400 ng). The total plasmid content was balanced up to
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625 ng with empty vectors when necessary. Cells were treated with TNF-alpha (10
ng/mL) or PBS for 6 hrs before luciferase assay was done using Dual-Luciferase
Reporter Gene Assay from Promega (Madison, WI).

In-vitro binding assay
Glutathione S-transferase (GST), GST-RelA (1-431), His-Tudor (UHRF1) and HisPRMT6 were isolated from Escherichia coli BL21 cells following 5 h induction with
IPTG. For GST fusion proteins, cells were harvested in PBS buffer plus protease
inhibitors, sonicated and centrifuged to remove cell debris. GST-fusion proteins
were purified by incubation with glutathione beads (Amersham Biosciences)
overnight with rotation at 4°C. Beads were washed five times and bound proteins
were eluted from the beads using freshly prepared reduced glutathione (33 mM).
For His-tagged proteins, cells were lysed in appropriate lysis buffer (containing 1mM
EDTA, 1mM EGTA, 5mM DTT and protease inhibitors), incubated with Ni-NTA
agarose (Qiagen Scientifics, Maryland) overnight with rotation at 4°C, then eluted
with elution buffer (containing 250mM imidazole).

10 ug of eluted GST fusion

proteins and His-PRMT6 were incubated in co-IP buffer [50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM EGTA, 15 mM MgCl2]
overnight at 4°C. Complexes were then pulled down with glutathione beads for 2 hrs
4°C, washed extensively in co-IP buffer and resolved on SDS-PAGE gel followed by
WB analysis.
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In vitro methylation assay
In vitro methylation reactions were carried out in 30 μl of phosphate-buffered saline
(pH = 7.4.), containing 0.5–1.0 μg of substrate, 3 μg of recombinant GST-PRMT6
and 0.42 μm [3H]S-adenosyl-l-[methyl-3H]methionine (79 Ci/mmol from a 7.5 μm
stock solution; PerkinElmer Life Sciences). The reaction was incubated at 30 °C for
1 h and then subjected to fluorography by separation on SDS-PAGE, transferred to
a PVDF membrane, treated with En3Hance™ (PerkinElmer Life Sciences), and
exposed to film for 1–3 days at –80 °C.

Isolation and culture of mouse primary keratinocytes
Briefly, 1-2 day old pups were sacrificed according to standard procedures and skin
was removed. Skins were placed on Trypsin-EDTA O/N 4 °C, then epidermis was
carefully removed from the dermis, chopped with sterile blades and transferred in
50-mL falcon tube containing Super media (with pen-strep, 10% FBS). Cells were
then strained through a 70 m strainer after mixing 5 times with a 10 mL sterile
pipette. Cells were left to adhere to a tissue culture dish for 3 hrs in Super media,
then the media was replaced with keratinocyte basal media (Lonza, cat.# CC-3158)
containing FBS 10%, pen-strep and additioned with components of the Lonza Kit
KGM-2 SingleQuots (Cat.# CC-4152).

Electroporation of primary MEFs
About one million cells were trypsinized and washed extensively with PBS, then resuspended in 800 L of PBS and pulsed using Bio-Rad Gene Pulser Xcell
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Voltage=500 Volts, Capacitance=600 farad and Resistance=

∞.

Cells were

immediately placed in complete media after electroporation.

Mammary organoid isolation
For mammary organoid isolation, we modified a protocol following Matthew J.
Smalley. 8-12 week-old female mouse was euthanized and dipped a few seconds in
70% EtOH. Using sterile material, the second, third and fourth pair of mammary
glands were removed, rinsed quickly in sterile PBS and placed in L15/10%FCS in a
tissue culture dish. Tissue was transferred into a clean, sterile tissue culture hood
and minced manually with sterile razor blades, then transferred to a 50-mL conical
polypropylene tube filled with 35 ml of working collagenase solution (prepared at the
moment) and incubated at 37 °C with vigorous agitation (1.5 hrs). Tissue was then
centrifuged 5 min, 1400 rpm and the supernatant transferred in a clean tube and the
centrifugation repeated. The two pellets were combined in 10mL L15/10%FCS
medium, transferred in a new 15-cm tube and centrifuged again. The pellet from this
centrifugation was re-suspended in 5 mL of red blood Lysis Buffer and left at room
temperature 5 min, then centrifuged (5 min 1400 rpm). This step was repeated one
more time. Pellet was then re-suspended in 10mL L15/10%FCS media and
centrifuged again. To remove most of mammary fibroblasts, the pellet was resuspend in DMEM/10% FCS and transferred to a T-80 tissue culture flask and
incubated in a regular cell incubator for 1.5 hr. Organoids were gently recollected,
transferred in 15-mL tube, centrifuged 5 min at 1400 rpm and re-suspended in final
media (DMEM/F12 (500 mL bottle) added with: 50 L FCS (10% final); 7L Pen-
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Strep; 500 L L-glatamine (4 M); 110 L (human or porcine) Insulin (10 mg/mL); 55
L EGF (Epidermal Growth Factor) (100 g/mL)).

Two-stage skin carcinogenesis
Dorsal skin from 6-8 week old mice was shaved 2 days before initiation. Initiation
was accomplished with a single application of 25 g DMBA and promotion by
applying 5 g TPA/week twice a week for 23 weeks, staring two weeks after
initiation. Both DMBA and TPA were dissolved in acetone (200 L/ one application).
The number and size of tumors where monitored weekly. Mann-Whitney U and X2
tests were run for statistical significance.

Evaluation of Ki-67 staining in the mammary gland
Mammary glands were stained for Ki67 and scanned using the Aperio slide scanner.
A GENIE morphometry algorithm was created that identified ductal epithelial tissue
in the glands and quantified the Ki67-positive nuclei within the epithelium. For each
slide, an area of mammary gland was selected in which staining artifacts were
minimal and no lymph nodes or other non-mammary tissue was present; the edges
of the tissues were excluded from the area selected to eliminate problems caused
by “edge effect”.

Statistical analysis
Where not specified, statistical analysis was performed using Student’s t-test.
* indicates p <0.05; ** indicates p <0.01; *** indicates p <0.001.
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Chapter 4
The ER*-PRMT6 mouse model
4.1 Characterization of tamoxifen-inducible ER*-PRMT6 chimera in cell lines
The hormone-binding domain of steroid receptors can be used as a regulatory
system to probe protein function (63). This approach has been used successfully to
generate conditional forms of transcription factors (c-Myc, Stat3, p53), kinases (cAbl & Raf1), DNA methyltransferase (MGMT) and Cre recombinase (63,64). The
development of a mutant estrogen receptor HBD (ER*) that is unable to bind
estrogen, yet retains normal affinity for the synthetic ligand, tamoxifen (Tamox) or 4Hydroxytamoxifen (OHT), has enhanced this approach (65). Human PRMT6 was
flag-tagged and fused to ER*, and then cloned into the pCAGGS expression vector
(Figure 6A). In this system, ER*-PRMT6 expression is driven by the ubiquitous actin promoter (66). To test the approach, this expression vector was stably
transfected into HEK 293 cells. In the absence of synthetic ligand, ER*-PRMT6 is
localized to the cytoplasm, upon Tamox- or OHT-treatment the chimeric protein no
longer interacts with the hsp90 complex, and is released for translocation into the
nucleus where it is stabilized and active (Figure 6B).

This is indeed what we

observed (Figure 6C). ER*-PRMT6 stable HEK 293 cells were fractionated into
nuclear and cytoplasmic parts and subjected to WB

analysis using an Flag

antibody. Prior to OHT-treatment, ER*-PRMT6 is restricted to the cytoplasmic
fraction. After OHT-treatment, ER*-PRMT6 translocates to the nucleus and steadily
accumulates there. Since PRMT6 is known to deposit the H3R2me2a mark (7-9),
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we isolated core histones from the same cells used for the fractionation study in
Figure 6C, and performed a WB analysis with an H3R2me2a antibody. Within two
days, the H3R2 site becomes heavily modified (Figure 6D).
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Figure 6. Characterization of an inducible ER*-PRMT6 fusion. (A) Human PRMT6 cDNA was cloned into the
pCAGGS vector, downstream an ER* (a truncated version of the estrogen receptor that binds tamoxifen). A
Flag-tag was introduced between the two proteins. The ubiquitous -actin promoter drives the expression of the
chimeric ER*-PRMT6 protein. (B) Graphic depiction of this approach. ER*-PRMT6 is localized in the cytoplasm.
Upon Tamox or OHT treatment the chimera protein becomes stabilized and translocates into the nucleus. C,
HEK293 cells stably transfected with pCAGGS ER*-PRMT6 were treatment with OHT (2 M) and then
separated into nuclear [N] and cytoplasmic [C] fractions. WB analysis was performed using an Flag antibody to
detect ER*-PRMT6. An Lamin A/C WB was performed to confirm the quality of the nuclear/cytoplasmic
fractionation. Time points after OHT-treatment are indicated. (D) Core histones were isolated from the same
ER*-PRMT6 HEK 293 cells shown in (C). The core histones were subjected to WB analysis with an H3R2me2a
antibody to monitor accumulation of this mark. Equal loading was confirmed by Ponceau staining and H3 WB
analysis.
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4.2 Characterization of tamoxifen-inducible ER*-PRMT6 transgenic mouse
lines
The pCAGGS-ER*-PRMT6 construct described above was used to generate three
founder transgenic mouse lines – A, B & C (Figure 7A). Lines A and C underwent
germ-line transmission, but Line C displayed low levels of transgene expression.
Subsequent studies were thus focused on transgenic Line A. Tamox was
administered to Line A mice by daily intra-peritoneal (IP) injections, for five days, as
previously described (67). At this point, we analyzed the expression levels of the
ER*-PRMT6 chimera in lysates generated from a number of organs (Figure 7B). In
addition, immunohistochemical analysis of ER*-PRMT6 localization in the liver
shows that IP administration of Tamox causes nuclear translocation and
accumulation of this chimeric protein in the nucleus (Figure 7C). Apart from IP
injection, Tamox can also be administered to the surface of the skin from where it is
absorbed for the activation of ER* fusion proteins in the epidermis (68), but this
delivery method also goes systemic. To determine whether ER*-PRMT6 could be
induced with topical Tamox-treatment, Line A transgenic mice were shaved dorsally
and painted with Tamox (1 mg) or vehicle (ethanol) daily for 5 days. We then
performed immunofluorescence (IF) using the Flag antibody on paraffin-embedded
skin sections and found that ER*-PRMT6 is strongly induced and localized to the
nucleus of epidermal cells in these mice (Figure 7D). Epidermal scrapes were also
collected from the Tamox-treated transgenic mice along with controls, and divided in
equal amounts for tissue lysates and core histone extraction in order to perform
PRMT6 and H3R2me2a WB analysis, respectively (Figure 7E). This experiment
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revealed that topical Tamox-treatment of transgenic Line A mice results in a marked
increase in H3R2me2a levels on the histone tail as a consequence of ER*-PRMT6
stabilization in the epidermis.
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Figure 7. The inducible ER*-PRMT6 fusion is functional in vivo. (A) Three transgenic lines were
established using the pCAGGS ER*-PRMT6 vector. Southern analysis was performed with a PRMT6
cDNA probe. The arrowhead indicates the transgene. (B) IP injection of 1 mg Tamox, for five
consecutive days, induced stabilization of ER*-PRMT6 in lung, brain and liver of Line A mice. The
vehicle (sunflower oil) was injected as a control. (C) Immunohistochemistry (IHC) using an Flag
antibody shows that upon IP injection of 1 mg Tamox (5 days) nuclear translocation of ER*-PRMT6 is
induced in the liver of Line A mice. The vehicle (sunflower oil) was injected as a control.
(D) Immunofluorescence for the Flag-tag performed on skin sections from transgenic Line A mice
shows ER*-PRMT6 stabilization in the nucleus when Tamox was applied topically on shaved dorsal
skin (1 mg/day) for 3 days. (E) Core histones were isolated from epidermal scrapes of topically
Tamox-treated mice (1 mg every other day for 10 weeks) and subjected to WB with an H3R2me2a
antibody.
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4.3 ER*-PRMT6 mice: An unexpected phenotype
Unexpectedly, ER*-PRMT6 transgenic mice that were subjected to daily topical
Tamox treatment all died within a 3-week period (Figure 8A). Death occurred more
rapidly (within 12 days) if Tamox (1 mg) was administered via IP injections (data not
shown). Lethality could be avoided by applying Tamox (1 mg) topically every second
day, although we did not observe a strong stabilization of the chimera in internal
organs with this treatment (data not shown). In an effort to determine the cause of
death of these mice, we performed several serum analyses, including evaluation of
inflammatory cytokines such as Interleukin 6 (IL-6), Tumor Necrosis Factor alpha
(TNF-alpha) and Interleukin 1 beta (IL-1), after topical application of Tamox (1 mg)
for 12 consecutive days. IL-6 serum levels were significantly elevated in the
transgenic Tamox-treated group (Figure 8B). The high variability observed in this
assay may be due to the anti-inflammatory effects of tamoxifen, which has been
shown to specifically interfere with NF-B activation (69-71). No significant
difference in TNF-alpha or IL-1 was detected (data not shown). Since mouse
keratinocytes are known to be a good source of IL-6 (72), we sought to confirm that
ER*-PRMT6 stabilization increased IL-6 transcription in the Tg Line A primary
keratinocytes. Therefore, we isolated these cells from newborn WT and Tg mice
(Figure 8C), cultured for one day, treated with OHT for 2 days (without replacing the
media), and stimulated with TNF-alpha 60 min prior to extracting RNA. As shown in
Figure 8D, the keratinocytes derived from transgenic mice also show a significant
increase in IL-6 transcription.
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Figure 8. ER*-PRMT6 mice die upon stabilization of the chimera and show increased IL-6. (A) The ER*PRMT6 Line A mice die upon prolonged Tamox administration. A survival curve generated after topical Tamox
administration (1 mg/day) until death of all transgenic mice occurred (n=14). WT mice were not impacted by this
treatment. (B) IL-6 serum levels after 12 topical application of Tamox (1 mg/day) were measured by ELISA. IL-6
serum levels (pg/mL) in four groups of animals (WT, WT Tamox treated, Tg Line A, Tg Line A Tamox-treated) are
shown. Wilcox and Student t-tests were run and a p value of 0.004 was obtained for the Tg Tamox-treated group (n=
32) when compared with the WT Tamox-treated group (n= 20) for both tests. All the mice in this study were healthy
at the time of serum harvest. All mice were between 8 and 9 week-old, and females and males were equally
represented. Primary keratinocytes isolation from 12 newborn mice (6 WTs and 6 Tgs) was performed (mice were
from two litters). All cells were cultured for two days, treated with OHT (1M) for 48 hrs, and then treated with TNFalpha for 60 min, at which point and RNA isolation and cell lysates were performed. (C) WB for the flag tag on cell
lysates shows stabilization of the ER*-PRMT6 in the Tg mice. A WB using keratin-5 antibody shows that these are
indeed keratinocytes (as negative control we loaded a cytoplasmic extract of Line A MEFs). (D) RNA was analyzed
by quantitative RT-PCR for the expression of IL-6 and normalized for GAPDH. The RQ difference between the two
groups of mice is statistically significant (p = 0.0335).
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4.4 PRMT6 interacts directly with the RelA subunit of NF-B
The Nuclear Factor-kappa B is known to regulate the expression of inflammatory
cytokines (28). PRMT family members CARM1 and PRMT1 have been shown to coactivate NF-B-dependent gene expression (36,38). Thus, we asked if PRMT6
might exhibit this function as well, which would explain the elevated levels of IL-6
observed in the Line A transgenic mice. We first asked if PRMT6 is in the NF-B
complex, by performing an immunoprecipitation (IP) using lysates of primary Mouse
Embryonic Fibroblasts (MEFs) from WT and Tg Line A mice using an anti-Flag
agarose. With this system we could co-IP endogenous RelA from the transgenic but
not the WT cells (Figure 9A). In order to exclude the possibility that the ER* portion
of the fusion protein could mediate this interaction, we transiently transfected HEK
293 cells with constructs expressing GFP, GFP-CARM1 or GFP-PRMT6 along with
a pCDNA-RelA vector for 48 hrs, then treated the cells with TNF-alpha for 30 min.
IP using GFP or IgG antibodies was performed on cell lysates. WB using RelA
antibody shows that RelA binds to GFP-CARM1 and GFP-PRMT6, but not to GFP
alone (Figure 9C). CARM1 has previously been reported to interact with RelA, and
it serves as a positive control in this experiment (36). A strong interaction was also
confirmed by transiently transfecting a Flag-PRMT6 (not fused to ER*) construct in
HEK 293 cells followed by co-IP experiments (Figure 9B). We were also able to coIP endogenous RelA by pulling down endogenous PRMT6 in HEK 293 cells (data
not shown).
The co-activators histone acetyltransferases p300 and its homolog, the
CREB-1-Binding Protein (CBP) are known to impact NF-B-dependent gene

41

expression and have been shown to interact directly with RelA (31). Moreover, NFB-dependent

gene

expression

involves

another

class

of

transcriptional

coactivators, the steroid receptor-coactivators (SRCs), which interacts with the p50
subunit of NF-B (32). PRMT6 has recently been shown to function as co-activator
of several nuclear receptors (i.e. progesterone, glucocorticoid, and estrogen
receptors) and to bind to SRC-1 in a mammalian two-hybrid assay (23). Therefore,
we questioned if PRMT6 interacts directly with RelA or if the binding is bridged by
other factors, such as SRC-1. For this purpose, GST and GST-RelA (1-431) were
incubated with His-PRMT6, and a GST pull-down experiment was performed. After
extensive washes, bound proteins were resolved on SDS-PAGE, followed by WB
analysis using His antibody. As a negative control, a GST-Tudor domain (UHRF1)
was incubated with His-PRMT6. As shown in Figure 9D, PRMT6 and RelA interact
directly in this in vitro assay.
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Figure 9. RelA co-immunoprecipitates with PRMT6 and they directly interact in vitro. (A)
Primary MEFs were isolated from WT and ER*-PRMT6 Line A mice, cultured for 7 days and treated
with OHT (2 M) for 24 hrs. Cells were then lysed and an immunoprecipitation (IP) was performed
using Flag agarose. A WB using RelA antibody reveals an interaction between the ER*-PRMT6
and the endogenous RelA in the lysate from the transgenic cells. (B) HEK 293 cells were transiently
co-transfected with a pCDNA-RelA vector and a pCAGGS-Flag-PRMT6 construct for 48 hrs, then
treated with TNF-alpha for 30 min. IP using Flag agarose was performed on the cell lysates. A WB
using RelA antibody shows that RelA is pulled down from the cells transfected with Flag-PRMT6,
but not from the Mock (cells transfected with pCDNA-RelA vector and empty pCAGGS vector). (C)
HEK 293 cells were transiently co-transfected with a pcDNA-RelA vector and constructs expressing
GFP, GFP-CARM1 or GFP-PRMT6 for 48 hrs, then treated with TNF-alpha for 30 min.
Immunopreciptation using GFP or IgG antibodies was performed on the cell lysates. A WB using
RelA antibody shows that RelA binds to GFP-CARM1 and GFP-PRMT6, but not to GFP alone. (D)
Direct binding between PRMT6 and RelA. GST and GST-RelA (1-431) were incubated with HisPRMT6 and a GST pull-down was performed. For an additional negative control, GST-RelA was
also incubated with a His-Tudor-UHRF1. A Western blotting using His antibody reveals direct
binding between GST-RelA and His-PRMT6.

43

4.5 PRMT6 is a coactivator of NF-B and its enzymatic activity is required for
this function
In order to test if PRMT6 functions as a co-activator of NF-B, we first performed a
luciferase assay using HEK 293 cells. PRMT6 overexpression increases the
luciferase activity of a NFB-Luc luciferase reporter plasmid (Figure 10A). We used
CARM1, a known co-activator for NF-B (36), as positive control for this experiment.
Furthermore, the enzymatic activity of PRMT6 is required for its co-activator function
(Figure 10B). This was established by transfecting HEK 293 cells with catalytic
active and inactive forms of PRMT6 (PRMT6 dead), and performing a NFB-Luc
luciferase assay. The inactive form of PRMT6 (VLD-KLA) has previously been used
in a similar assay (14).
To further confirm that PRMT6 functions as a coactivator of NFB, we
performed quantitative real-time PCR experiments, in which we asked if, by
overexpressing PRMT6 in HeLa cells, the transcription of IL-6 increases upon TNFalpha stimulation. We transfected HeLa cells with constructs expressing GFP, GFPPRMT6 or GFP-CARM1 (as positive control), and we observed enhanced
transcription of IL-6 when either PRMT6 or CARM1 were overexpressed (Figure
10C). We also explored the expression levels of several other genes known to be
activated in HeLa cells upon TNF-alpha stimulation. These included TNF-alpha,
Monocyte chemotactic protein 1 (MCP-1/CCL-2), Cyclooxygenase 2 (COX-2) and
IkB-alpha (73). Among these genes, we found that PRMT6 co-activates TNF-alpha,
MCP-1 and COX-2 (Figure 10C).
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We then sought to understand if PRMT6 is essential for kB-dependent
transactivation function. To this scope, we took advantage of PRMT6 KO MEFs
availability in out laboratory (the PRMT6 KO mice were a gift from Dr. Stephane
Richard) and performed Real-Time experiments with them. In this experiment, we
treated WT, PRMT6 KO and CARM1 KO cells with TNF-alpha for 2 hrs and then
extracted the RNA. As shown in Figure 10D, the PRMT6 and CARM1 cells display
a significant reduced transactivation at the IL-6 locus compared to the WT cells.
Therefore, although both PRMT6 and CARM1 enhance the transactivation of NF-kB
at the IL-6 locus, neither of them is essential for this function. These data are in
agreement with the observations from the Hottiger’s group, who also did not see a
defect in IL-6 activation in these CARM1 KO MEFs (36).
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Figure 10. PRMT6 is a NF-B coactivator. (A) HEK 293 cells were transiently co-transfected with a NF-B firefly
luciferase reporter plasmid and a renilla luciferase construct along with a GFP vector (Mock), a GFP-CARM1, or a
GFP-PRMT6 construct. Cells were left un-stimulated or stimulated 20 hrs after transfection with TNF-alpha (10 ng/mL,
6 hrs). Error bars represent standard deviation calculated from quadruplicate luciferase assays. Mean values are
expressed as fold changes in luciferase activity with the un-stimulated Mock arbitrarily set as 1. The p values obtained
for PRMT6 and CARM1 transfections compared to the Mock are 0.00016 and 0.0012, respectively, when a two sample
independent t-test is run. These data are representative of four independent experiments. (B) HEK 293 cells were
transiently co-transfected with a NF-B luciferase reporter plasmid and a renilla luciferase construct along with an
empty vector or pMyc-PRMT6 or a PRMT6 catalytic inactive form (dead). Cells were un-stimulated or stimulated 20 hrs
after transfection with TNF-alpha (10 ng/mL, 6 hrs). Error bars represent standard deviation calculated from
quadruplicate luciferase assays. The p value obtained for the WT PRMT6 transfection is 0.0006, when a two sample
independent t-test is run. (C) HeLa cells were transfected with GFP (Mock), GFP-PRMT6 or GFP-CARM1 constructs
for 24 hrs and then stimulated with TNF-alpha (10 ng/mL) for 60 min. Total RNA was analyzed by quantitative RT-PCR
for the expression of the indicated genes and normalized against GAPDH. For each gene, the TNF-alpha stimulated
Mock group mean was arbitrarily set as 1. Error bars represent standard deviation calculated from triplicates. The
asterisk indicates statistically significant difference compared to the Mock when a two sample independent t-test is run.
For IL-6, the p values for GFP-PRMT6 and GFP-CARM1 versus Mock are 0.005 and 0.0004, respectively. For TNFalpha the p values for GFP-PRMT6 and GFP-CARM1 versus Mock are 9.2E-07 and 0.002 respectively. For MCP1 the
p values for GFP-PRMT6 and GFP-CARM1 versus Mock are 0.3 and 0.07, respectively. For COX-2 the p values for
GFP-PRMT6 and GFP-CARM1 versus Mock are 5.8E-05 and 0.64, respectively. (D) WT, PRMT6 KO and CARM1 KO
MEFs were left untreated or stimulated with TNF-alpha for 2 hrs before RNA was extracted. Total RNA was analyzed
by quantitative RT-PCR for the expression of IL-6 gene and normalized against GAPDH. The mean value for the
unstimulated groups was arbitrarily set as 1. Error bars represent standard deviation calculated from triplicates. The
asterisks indicate significant difference of these groups compared to the WT. The p values for TNF-alpha stimulated
PRMT6 and CARM1 KO versus the WT cells are 0.0014 and 0.0038, respectively.
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4.6 PRMT6 causes nuclear shuttling of RelA
Having established that PRMT6 coactivates NF-B, we investigated the possible
mechanism for this function. First, we explored the possibility that, when overexpressed, PRMT6 may promote the movement of NF-B into the nucleus. For this
purpose, we isolated primary MEFs from WT and ER*-PRMT6 embryos and treated
them with OHT for 2 weeks. Cells were then fractionated and subjected to WB
analysis using a RelA antibody. We observed an increase of nuclear RelA upon
the Tamox-induced stabilization of ER*-PRMT6 in the nuclear fraction (Figure 11A).
This effect on RelA nuclear shuttling was seen in MEFs isolated from additional
embryos (data not shown). No change in global levels of RelA was observed in
primary MEFs (Figure 11B). In order to confirm this phenomenon we performed IF
in HeLa cells upon transient transfection with a GFP-PRMT6 construct. A GFPexpressing construct was transfected in parallel for negative control. As shown in
Figure 11C, cells overexpressing PRMT6 (which localizes strongly in the nucleus)
show increased RelA in the nucleus. Thus, the overexpression of both GFP-PRMT6
and ER*-PRMT6 causes increased nuclear RelA. This established that the ER*
component of the ER*-PRMT6 fusion is not responsible for this translocation of
RelA, but rather it is the PRMT6 protein itself.
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Figure 11. PRMT6 promotes RelA shuttling into the nucleus (A) Primary MEFs were isolated from WT
and ER*-PRMT6 mice, cultured for 3 days and treated with OHT for 2 weeks. Cell fractionation was
performed. WB analysis for the Flag-tag shows stabilization of ER-PRMT6 in the nuclear fraction,
corresponding to increased nuclear RelA. (B) Primary MEFs were isolated from 2 WT and 2 ER*-PRMT6
mice, cultured for 3 days and treated with OHT for 3 days. Total cell lysates were analyzed by WB using
RelA and Flag antibodies. Cells in which the ER*-PRMT6 is overexpressed do not show increased total
levels of RelA. (C) Immuno-fluorescence using a RelA antibody following transient transfection of GFPPRMT6 in HeLa cells shows increased nuclear RelA in transfected cells. A GFP-expressing construct was
used as negative control.
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4.7 A methylation-dependent mechanism for PRMT6 coactivator function
The mechanism for PRMT6 co-activation is clearly methylation-dependent, as
shown in Figure 10B. Posttranslational modification of RelA by PRMT6 could
account for its increased nuclear localization. We thus tested the possibility that
PRMT6 may methylate RelA by performing in vitro methylation assays. In this in
vitro methylation assay, we observed robust methylation of histone H3, as well as
automethylation of PRMT6 itself, but no methylation of recombinant RelA (Figure 12
A,B). We then hypothesized that the coactivation is associated with the PRMT6
action on the histone code. As mentioned above, PRMT6 has been shown to
methylate the R3 position of the N-terminal tails of histones H4 in in-vitro reactions
(9). Thus, we questioned if the ability of PRMT6 to function as a co-activator may be
linked to its capacity to also methylate the R3 position of the N-terminal tails of
histones H4 in vivo, generating the active H4R3me2a mark. To test this hypothesis,
we utilized a specific H4R3me2a antibody and performed WB analysis on core
histones isolated from primary MEFs of WT and Line A mice. As shown in Figure
13A, ER*-PRMT6 Line A MEF core histones show a global increase in H4R3me2a
when PRMT6 is stabilized in the nucleus by Tamox treatment for two weeks. To
further confirm this, we transiently transfected HEK 293 cells with a pCAGGS-FlagPRMT6 construct and looked by WB. In this experiment, we saw a more dramatic
global elevation of the H4R3me2a activating mark (Figure 13B). As PRMT1 is
known to be the primary enzyme generating the H4R3me2a mark, we sought to test
if PRMT6 could rescue this mark when PRMT1 is knocked out (KO). We took
advantage of the availability of an OHT-inducible PRMT1 KO stable line, previously
described (74), which we stably transfected with our ER*-PRMT6 construct. As
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shown in Figure 13C, while the PRMT1 KO cells have a dramatic reduction in the
H4R3me2a mark upon OHT treatment, the stable line we generated shows rescue
of this mark upon concomitant loss of PRMT1 and overexpression of PRMT6 (ER*PRMT6), therefore PRMT6 is able to maintain the H4R3me2a modification in
absence of PRMT1.
We then asked if PRMT6, like CARM1 (36), might be recruited to the IL-6
promoter upon TNF-alpha stimulation and if the H4R3me2a mark concomitantly
increases at this locus, therefore we performed chromatin immunoprecipitation
(ChIP) using PRMT6, H4R3me2a and H3R2me2a antibodies. We clearly observe
enrichment of PRMT6 and H4R3me2a at the transcriptional start site (TSS) of IL-6
upon TNF-alpha stimulation (Figure 14). These data strongly suggest that PRMT6
is recruited to chromatin with RelA, where it impacts the histone code and/or
possibly methylates other chromatin-associated proteins to facilitate transcription at
the IL-6 locus.
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Figure 12. PRMT6 does not methylate RelA in vitro. (A) GST-PRMT6 was incubated with
recombinant histone H3, GST, or GST-RelA (1-431) and the methyl-donor tritiated S-adenosylmethyonine (SAM) for 30 min. The reactions were then resolved by SDS-PAGE and transferred to a
PVDF membrane. A fluorography revealed strong activity of PRMT6 on recombinant histone H3, while
no activity was detected on RelA (1-431). (B) Flag-PRMT6 was pulled down from HEK 293 cells upon
TNF-alpha stimulation (10ug/mL, 30 min.) and incubated with histone H4 or GST-RelA (1-431).
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Figure 13. PRMT6 generates the H4R3me2a active mark in vivo. A, Primary MEFs were isolated from
WT and ER*-PRMT6 mice, cultured for 3 days and treated with OHT for 2 weeks. Cell fractionation and
core histone isolation was performed. A WB for Flag shows stabilization of the ER-PRMT6 in the nuclear
fraction from the Tg OHT-treated cells. A WB on core histones shows increased H3R2me2a as well as
H4R3me2a global levels in the Tg OHT-treated cells. B, HEK 293 cells were transiently transfected with a
pCAGGS-Flag-PRMT6 vector or an empty vector (Mock) and a WB for PRMT6 showed a highly efficient
expression of the exogenous flag-PRMT6 compared to the endogenous, while PRMT1 levels were
unchanged. A WB for Actin was used for loading control. Core histones from these cells were extracted and
subjected to WB using H4R3me2a and H3R2me2a antibodies, which revealed an increase of these
marks in the cells over-expressing Flag-PRMT6, while H4R3me2s or H3K4me3 levels did not change. C, An
OHT-inducible PRMT1 knockout MEF line (PRMT1FL/- ;ER-Cre), previously described, was stably transfected
with our ER-PRMT6 construct. Cells were left untreated or treated with 2M OHT along with the MEF
inducible PRMT1 knock-out cells and a MEF control line (PRMT1+/+ ;ER-Cre) for 7 consecutive days. WB for
PRMT1 and PRMT6 on cell lysates were performed. A WB for beta-Actin is shown for loading control. Core
histones from the cells were extracted and a WB for H4R3me2a was performed. A WB for Histone H4
showed equal histone loading.
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Figure 14. PRMT6 ChIPs at the TSS of IL-6, with concomitant increase in the H4R3me2a
mark upon TNF-alpha stimulation. HeLa cells were transiently transfected with a Flag-PRMT6
construct, and a ChIP assay was performed using Flag, H3R2me2a and H4R3me2a
antibodies. Upon TNF-alpha stimulation (60 min), PRMT6 is enriched at the transcriptional start
site (TSS), corresponding to the consensus region for NF-kB. The H3R2me2a repressive mark
is unchanged, while the H4R3me2a active mark is significantly enriched.
Error bars represent standard deviation calculated from triplicates. Mean values are fold
changes compared to the IgG and normalized to a control intergenic region about 8000bp
upstream the TSS. The asterisk indicates statistically significant difference compared to the unstimulated when a two sample independent t-test is run.
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Chapter 5
The Cre-inducible mouse model
5.1 The Cre-inducible system
A Cre-inducible hPRMT6 transgene was cloned using the pCAGGS vector, which
harbors a beta-actin promoter. Between the promoter and PRMT6 we placed a Stop
cassette, which is flanked by directly repeated loxP sites (Figure 15A). This Stop
cassette terminates transcripts, as previously described (62), and is excised by the
action of a Cre recombinase. The excision capability of a Cre recombinase was first
tested in vitro, by transforming the stop-cassette containing vector in a Creexpressing E. coli strain. With this system, the linearized construct isolated from this
strain is shorter than the linearized construct used to transform the cells, due to the
stop-cassette excision, therefore a gel shift of about 1,400bp (the stop cassette
length) can be appreciated (Figure 15B).
Before attempting to generate mice, the inducible expression of the FlagPRMT6 was also tested in cultured cells by performing WB analyses with an Flag
antibody upon co-transfection of HEK 293 cells with the pCAGGS-stop-PRMT6
construct and a GFP-Cre expressing vector (Figure 15C). For positive control (last
lane on the right) we transfected cells with the construct isolated from Creexpressing E. coli (Figure 15B, lane 2), which, as expected, gives a very efficient
expression of the Flag-PRMT6. To ascertain that the stop cassette was efficient in
blocking transcription, we also transfected cells with the pCAGGS-stop-PRMT6
construct, which, as expected, does not express Flag-PRMT6.
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Figure 15. PRMT6 is re-expressed from a pCAGGS-stop-PRMT6 construct upon Cre
recombination. (A) Depiction of the Cre-inducible PRMT6 construct. A Flag-hPRMT6 cDNA was cloned
into the pCAGGS vector, downstream a loxPeta-actin promoter
drives the expression of the Flag-PRMT6 transgene. Upon Cre recombination, the stop cassette is
excised and a loxp-Flag-PRMT6 is left. (B). The system was tested for Cre recombination by using a
Cre-expressing E. coli strain. In lane 1 is the pCAGGS-stop-PRMT6 linearized construct, while in lane 2
is the same construct after transformation and isolation from the Cre-expressing E. coli. A gel shift is
indicative of proper excision of the stop cassette. (C) HEK 293 cells were transfected with an empty
pCAGGS vector (Mock) or a pCAGGS-stop-PRMT6 construct along with a GFP-Cre vector, or a
pCAGGS-stop-PRMT6 construct or a pCAGGS-loxp-PRMT6 construct. After 24 hrs, cells were
harvested and a WB for Flag was performed on the cell lysates.
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5.2 Ex vivo characterization of Cre-inducible mouse lines
The construct described above was employed to generate transgenic mouse lines,
which we call STOP-PRMT6 mice. From a first pronuclear injection we obtained 2
lines (Line 1 and 2) (Figure 16A, left), but neither line re-expressed the transgene
upon Cre recombination. From a second pronuclear injection we obtained three
additional lines (Line 3, 4, 5) (Figure 16A, right), all of which showed re-expression
of the transgene upon Cre recombination. To test the re-expression of Flag-PRMT6
we isolated primary MEFs from these mouse lines, transfected them with a GFP-Cre
vector, and tested the expression of the transgene by WB using a specific antihPRMT6 antibody. As seen in Figure 16B, Line 1 and 2 do not re-express
exogenous PRMT6 upon Cre recombination, while Line 3, 4, 5 re-express the FlagPRMT6. The double band present in all the lanes is a non-specific doublet
recognized by the specific anti-hPRMT6 antibody in use. To further confirm
expression of Flag-PRMT6 we also performed IF analyses on all the lines using
anti-Flag antibody. For Line 1 and 2 we did not see re-expression of Flag-PRMT6
(data not shown), while for Line 3, 4, 5 we confirmed the re-expression (Figure
16C). In this IF, the green nuclei (which are the ones transfected with GFP-Cre) are
indeed positive for Flag staining (in purple).
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Figure 16. Characterization of STOP-PRMT6 MEFs. (A) Five transgenic lines were established using the
pCAGGS-stop-PRMT6 vector. Southern analysis was performed with a PRMT6 cDNA probe. The arrowhead
indicates the transgene. (B) Primary MEFs were isolated from Line 3, 4 and 5 and cultured for 7 days, then an
electroporation using a pCAGGS-GFP-Cre vector was performed. Cells were harvested 24 hrs later and a WB using
a specific anti-hPRMT6 antibody was performed. The double band that appears under the specific human PRMT6
and s present in the negative control cells is an a-specific band. (C) An aliquot of primary MEFs from the
electroporation described in (B) was plated on coverslip and an IF using anti-Flag antibody was performed.
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5.3 Crossing the STOP-PRMT6 lines with K5-Cre mice
We crossed Line 3, 4 and 5 to keratin 5 (K5)-Cre transgenic mice (75). The K5-Cre
mouse line was chosen because PRMT6 is overexpressed in a number of epithelial
cancers (lung, breast, cervical and bladder cancer – Figure 5E), where the K5
promoter is active. This line is on a FVB background and was available in Science
Park from Dr. David Johnson’s laboratory. When crossed with K5-Cre, all three lines
generated bigenic pups that were slightly smaller than their single transgene (or
WT) littermates and displayed a delay in hair development (Figure 17A), although
these differences were not appreciable once the mice reached adulthood. At
histological level, a hair follicle phenotype was observed. Indeed, hair follicle were
somewhat disorganized, with the appearance of transversally oriented hair follicles
which embedded in the fat layer (Figure 17B, arrowhead). The bigenic mice of Line
4 displayed the most severe phenotype at both gross and histological levels.
Epidermal scrapes were performed on the skin from the bigenic mice of the three
lines, and these lysates were subjected to WB analysis using anti-hPRMT6
antibody, which revealed expression of the exogenous form of PRMT6 in all the
lines (Figure 18A). Although the expression of Flag-PRMT6 seemed to be good in
WB analyses, IF analyses revealed a very focal expression in both epidermis and
hair follicles in all the lines. In Figure 18B is shown the IF for the Flag-tag on
paraffin embedded skin sections of STOP-PRMT6/K5-Cre (Line 4) mice.
Since STOP-PRMT6 bigenic mice of Line 4 harbor the least transgene copy
number (Figure 16A), show the strongest Flag-PRMT6 expression in the epidermis
and the most obvious hair follicle phenotype (Figure 17), we decided to focus on
this line for further characterization and experiments. We will refer to the Line 4 as
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STOP-PRMT6 from here on. In addition to the epidermis, the K5-Cre transgene is
also expressed in a number of other stratified and pseudo-stratified epithelial
tissues, including the cervix, vagina, oral and nasal cavities, esophagus, stomach,
bladder, lung, thymic epithelial, prostate, and myoepithelial cells of the mammary
gland (76), therefore we performed a WB analysis on lysates from several organs of
the STOP-PRMT6/ k5-Cre bigenic mice using a antih-PRMT6 antibody. As seen in
Figure 19A, the expression of exogenous PRMT6 is predominant in epidermis,
mammary gland and thymus. A residual expression was seen in brain and liver.
Next, we analyzed the core histones isolated from STOP-PRMT6/K5-Cre epidermal
scrapes. We observed a clear elevation of H3R2me2a levels in the bigenic mice
(Figure 19B) by WB. Finally, we performed double immuno-fluorescent staining
using anti-H3R2me2a (green) and anti-Flag (red) antibodies on paraffin-embedded
sections from the skin of STOP-PRMT6/K5-Cre bigenic mice. We observed a
dramatic elevation of H3R2me2a levels in cells expressing Flag-PRMT6 (Figure
19C). These data show that the Tg4 line has an altered histone code and provides
in vivo evidence for PRMT6 impacting epigenetic signatures.
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Figure 17. Bigenic mice of the K5-Cre cross display a hair phenotype. (A) Pups of each STOPPRMT6 line that we obtained (Line 3, 4, 5) display delayed hair onset upon Cre recombination. (B) H&E
sections of 3-week-old STOP-PRMT6/ K5-Cre mice showing the hair follicle phenotype.
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Figure 18. The expression of Flag-PRMT6 is extremely focal in the skin of bigenic mice. (A)
Epidermal scrapes were collected from bigenic mice of the three lines of the STOP-PRMT6 mice
that we generated and subjected to WB analyses using a specific anti-hPRMT6 antibody. (B) Skin
sections from bigenic STOP-PRMT6/K5-Cre (Line 4) mice were paraffin embedded and subjected to
IF staining using anti-Flag antibody.
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Figure 19. STOP-PRMT6/ K5-Cre mice display elevated H3R2me2a mark. (A) Organ lysates from
a STOP-PRMT6 /K5-Cre mouse were subjected to WB analyses using a specific anti-hPRMT6
antibody. (B) Epidermal scrapes from a bigenic and a control mouse were collected and divided in two
parts to perform WB analyses for PRMT6 and H3R2me2a on lysates and core histones, respectively.
(C) Sections from skin of bigenic mice were paraffin embedded and a co-IF was performed using
mouse anti-Flag (red) and rabbit anti-H3R2me2a (green) antibodies.
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5.4 A chemical skin carcinogenesis study on STOP-PRMT6/K5-Cre mice
Having observed a gross skin phenotype in live K5-Cre/STOP-PRMT6 bigenic mice
and demonstrated overexpression of PRMT6 and increased levels of the PRMT6mediated H3R2me2a mark in bigenic epidermis, we hypothesized that pathological
effects of PRMT6 overexpression in the epidermis and possibly other K5-expressing
tissues may be detectable. The gross skin phenotype that is observed in our bigenic
lines, including the alopecia, is similar to the phenotype observed for a number of
other K5 transgenic models that have hyperplastic and hyperproliferative epidemis,
including K5 models that overexpress Myc (77) and E2F1 (78). These models also
develop spontaneous tumors in the skin and other K5-expressing tissues. Moreover,
deregulated expression of Myc in the epidermis of transgenic mice resulted in an
enhanced response to two-stage skin carcinogenesis (77). We hypothesized that
STOP-PRMT6/K5-Cre bigenic mice may have increased susceptibility to skin
carcinogenesis as well.

This is consistent with the strong correlative data

demonstrating that PRMT6 is overexpressed in several different human cancers. In
order to test our hypothesis we carried out a two-stage DMBA/TPA skin
carcinogenesis study on STOP-PRMT6/K5-Cre mice. Mice were initiated by
applying 25μg DMBA once and promotion was performed applying 5μg TPA/week
twice a week for 23 weeks, following the protocol from the group of Yuspa (79). As
control group the K5-Cre mice were included in this study. We compared a number
of endpoints, including tumor incidence, burden, multiplicity, and malignancy. A two
group Chisq test with a 0.050 two-sided significance level will have 80% power to
detect the difference between a Group 1 proportion of 0.3 and a Group 2 proportion
of 0.7 when the sample size in each group is 25. Therefore, we included 27 bigenic
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mice in this study. When we examined papilloma incidence, number, and burden
we did not observe significant difference between the STOP-PRMT6/K5-Cre bigenic
group and the control group (Figure 20). When we examined the number of
squamous cell carcinomas (SCC) and spindle cell carcinomas (SCT) we also did not
detect significant difference between the two groups. However, spindle cell
carcinomas, which are believed to represent a more advanced form of SCC, were
absent in the control group while 5 total were detected in the bigenic group.
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Figure 20. Results of the chemical skin carcinogenesis study. (A) Papilloma incidence during the 23-week
TPA treatment. Tumors were counted every second week. (B) Tumor burden (cumulative for all the mice),
expressed in cm. (C) Tumor multiplicity, expressed in number of papillomas/mouse. (D) Analysis of the
malignancies at the endpoint of the carcinogenesis study (mice were sacrificed at 23 weeks of TPA
administration). MiSCC, Microinvasive Squamous Cell Carcinomas: SCC, Squamous Cell Carcinomas; SCT,
Spindle Cell Carcinomas.

65

5.5 A cancer study on STOP-PRMT6/K5-Cre;p53+/- mice to investigate the role
of PRMT6 in tumorigenesis
The p53+/- mice exhibit a wide array of tumors, including soft tissue sarcomas,
osteosarcomas and carcinomas of various types starting at about 9 months of age
(80). In order to determine if increased PRMT6 activity cooperates with p53
deficiency in tumor development we generated STOP-PRMT6/K5-Cre;p53+/- mice.
These mice were all 100% FVB. The breeding scheme to generate these mice is
shown in Figure 21. As shown in Figure 19A, the expression of the exogenous
hPRMT6 is quite extensive in the bigenic STOP-PRMT6/K5-Cre mice, therefore the
impact of PRMT6 overexpression on tissue homeostasis and malignancy could be
examined in a variety of organs using this model system.

Importantly, PRMT6

overexpression is observed in tumors from several of the tissues that are targeted
by the K5 transgene, including the cervix, bladder, lung and breast (Figure 5E). In
performing this cancer study, we hypothesized that increased PRMT6 expression
and activity would cooperate with p53 inactivation to accelerate tumor development,
and we were especially interested in potential effects of PRMT6 overexpression on
mammary tumor development. We calculated that 20 double transgenic mice should
be enough to detect a statistically significant difference between the control and the
experimental groups. [If PRMT6 over-expression increases tumor incidence to 80%
by one year, then 20 mice per group will be enough to detect a statistically
significant difference in tumor incidence (a two group chi-square test with a 0.05 one
sided significance level will have 80% power to detect the difference between 40%
and 80% when the sample size is each group is 18)]. We obtained total of 34
bigenic mice (females and males were equally represented in the group) and
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monitored them for tumor formation over 10-month period along with the K5-Cre
control group (Table 1). Complete necropsy was performed by Dr. Donna Kusewitt
and any lesion or abnormal looking organ was taken for histopathological analysis
when mice were about 9 months old. It has to be noted that we experienced a loss
of about 25-30% of mice from each group during the time period of this study (Table
1). Deaths were sudden and started around 5 months of age. We did not investigate
on the cause of deaths, especially considering that this was a phenomenon
happening for all the groups. Mice that died before the endpoint of this study were
therefore discarded. Overall, in this study there was not a significant difference in
tumorigenicity between the two groups, but the bigenic mice showed signs of
increased inflammation.
Consistent with our findings about PRMT6 role in inflammatory response
described in Chapter 4, overall there appeared to be increased inflammation
(perivasculitis in the lung and kidney and microabscess in the liver) in the STOPPRMT6/K5-Cre females compared to the K5-Cre control females (Figure 22,
arrowheads) although the difference was not statistically significant, probably due to
the inadequate number of females left at necropsy. This phenomenon was not seen
in the males.
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Figure 21. Breeding scheme to generate STOP-PRMT6/K5-Cre;p53+/- mice.
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Table 1. Control and transgenic mice employed in the cancer susceptibility study.

Figure 22. STOP-PRMT6/K5-Cre females from the tumor study (p53+/- cross) display
perivasculitis in the lungs and microabscess in the liver. Representative H&E staining of liver and
lungs of K5-Cre control and STOP-PRMT6/K5-Cre bigenic females. Arrowheads indicate
microabscess and perivasculitis. (Pictures taken by Dr. Donna Kusewitt).
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5.6 Crossing the STOP-PRMT6 mice with a MMTV-Cre mouse line
Transgenic mouse lines carrying a Cre recombinase under the control of the MMTV
LTR (MMTV-Cre, Line A and Line D) have been generated by the group of
Hennighausen (81,82). We crossed our transgenic STOP-PRMT6 with the MMTVCre Line D, which was available in Science Park from Dr. Marcelo Aldaz’ group.
This strain originated on an FVB background, but has been backcrossed to
B6129F1 and is now only available in this background from the Jackson’s
repository. MMTV-Cre Line D mice display high levels of recombination in the virgin
and lactating mammary gland, salivary gland, seminal vesicle, skin, erythrocytes, B
cells and T cells when crossed to ROSA26-lox-Stop-lox-LacZ reporter strain, while
little background recombination is observed in the lung, kidney, liver and brain
tissues (less than 10%) (81). In crossing STOP-PRMT6 mice with MMTV-Cre mice
we kept the background at 50% FVB component.
We first sought to compare the expression level of the exogenous PRMT6 in
the bigenic STOP-PRMT6/MMTV-Cre mice versus the bigenic STOP-PRMT6/ K5Cre mice, therefore we harvested mammary gland tissue and performed WB
analyses using anti-hPRMT6 antibody - which revealed an equal level of expression
in these two crosses (Figure 23A) - as well as immunohistochemistry (IHC) staining
on paraffin embedded tissue using anti-Flag antibody (Figure 23B). The IHC shows
extensive (although mosaic) expression of the exogenous PRMT6 in mice from both
crosses, but there seems to be a difference in the compartment of cells that express
the exogenous Flag-PRMT6: the K5-Cre cross appears to be mostly luminal, while
the MMTV-Cre cross appears to be both myoepithelial and luminal. In order to
evaluate the level of over-expression of the exogenous PRMT6 in comparison to the
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endogenous protein and the histone arginine methylation status in the epithelial
compartment of the mammary gland, we isolated primary mammary epithelial cells
(organoids) from the bigenic STOP-PRMT6/MMTV-Cre mice along with the controls
(single transgenic STOP-PRMT6 mice). As shown in Figure 24A, WB analysis on
the cell lysates using an anti-PRMT6 antibody (which recognizes human and mouse
PRMT6) reveals a strong over-expression of the exogenous Flag-PRMT6 compared
to the endogenous protein. WB analyses were performed on core histones isolated
from these cells to investigate levels of asymmetric dimethylation on H3R2 as well
as H4R3. As shown in Figure 24A the global H3R2me2a and H4R3me2a (although
to a lesser extent) levels are elevated in the mammary gland epithelium from the
double transgenic mice compared to the single transgenic controls. We then took
advantage of the mosaic expression displayed by the Tgs STOP-PRMT6/MMTVCre mice to perform double immuno-fluorescence for the Flag-tag and the histone
marks of our interest. The epithelial mammary gland cells from the double
transgenic mice that do not express the exogenous Flag-PRMT6 (red) display lower
H3R2me2a and H4R3me2a, shown in green (Figure 24B). Therefore, we were able
to confirm that PRMT6 methylates the H4R3 site in vivo with these mice.
Since PRMT6 impacts epigenetic signatures in vivo in our mouse model, we
questioned if PRMT6 may induce increased proliferation in the mammary gland of
the bigenic mice. For this evaluation (done by Dr. Donna Kusewitt) we examined the
proliferative marker Ki-67, as described in the Materials and Methods Chapter. For
STOP-PRMT6/K5-Cre mice, we utilized the females from the tumor study described
in Section 5.5, but we did not detect any difference between the K5-Cre control
group and the bigenic STOP-PRMT6/K5-Cre group (data not shown), however we
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did see a difference in Ki-67 staining for the bigenic STOP-PRMT6/ MMTV-Cre mice
compared to the control groups (WT, STOP-PRMT6, and MMTV-Cre)

(Figure

25A). We also examined the percentage of the area that was composed by ducts in
the four groups. Interestingly, the percentage of the area examined that was
composed of ducts in the MMTV-Cre mice was higher, although not statistically
significant, than the WT and STOP-PRMT6. The percentage of the area occupied
by ducts was higher in the bigenic mice compared to control groups MMTV-Cre, WT
and STOP-PRMT6, although the p value was significant only when the comparison
was done with the WT and STOP-PRMT6 groups (Figure 25B). In more simple
terms we can summarize these data by stating that the MMTV-Cre mice per se
display more epithelialization than WT mice, but the overexpression of PRMT6 in
these mice seems to increase this phenotype.
Having ascertained a hyper-proliferative phenotype in the mammary gland of
the bigenic STOP-PRMT6/MMTV-Cre mice, we set-up an ageing study to
investigate the possibility of increased spontaneous mammary carcinogenesis in
these mice compared to the controls. These mice have been aged until 12 months
and analyses on the mammary tissue are currently underway. Some of the bigenic
mice have developed large mammary tumors, which are being examined by our
pathologist.
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Figure 23. Flag-PRMT6 expression analysis in the mammary gland of bigenic STOP-PRMT6/MMTVCre mice. (A) STOP-PRMT6 mice were crossed with a K5-Cre mouse line and a MMTV-Cre mouse line.
WB analysis on the mammary gland extracts using an anti-hPRMT6 antibody shows expression of the
exogenous PRMT6 in the bigenic females from each cross. (B) Immuno-histochemistry using an anti-Flag
antibody on paraffin embedded mammary gland tissue is shown here.
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Figure 24. Bigenic STOP-PRMT6/MMTV-Cre mice display elevated histone arginine
methylation in the mammary gland epithelium. Primary mammary epithelial cells were isolated
from bigenic STOP-PRMT6/ MMTV-Cre and control (single transgenic) females and cultured for 3
days. (A) Cell lysates were subjected to WB analysis using an aPRMT6 antibody which recognizes
human and mouse PRMT6. Core histones were isolated and subjected to WB analysis using
H3R2me2a and H4R3me2a specific antibodies. (B) Double immuno-fluorescence using
Flag/H3R2me2a or Flag/H4R3me2a antibody combinations was also performed.
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Figure 25. STOP-PRMT6 /MMTV-Cre female mice display increased proliferation in the mammary
gland. The fourth mammary glands from 13-14 week-old females were paraffin-embedded and stained for
the proliferative marker Ki-67. The groups of mice under evaluation were WT (n=7), MMTV-Cre (n=6),
STOP-PRMT6 (n=7) and bigenic STOP-PRMT6/MMTV-Cre (n=7). (A) Evaluation of number of Ki-67
positive nuclei per mm 2 duct tissue. The p value is 0.015 when the bigenic group is compared to the MMTVCre group. (B) Percentage of the selected area that was identified as being occupied by ducts. For statistical
analysis, the Student t test was used. Values are for a 2-tailed t-test assuming unequal variance. p values
are 0.014, 0.046 and 0.38 when the bigenic group is compared to the WT, STOP-PRMT6 and MMTV-Cre
group, respectively.
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5.7 A RNA-Seq experiment to investigate the impact of PRMT6 overexpression
on mammary gland transcriptome
Since two regulatory histone marks, namely H3R2me2a and H4R3me2a, are
aberrantly methylated in the mammary gland of the bigenic STOP-PRMT6/ MMTVCre mice, we sought to investigate the impact of PRMT6 over-expression on the
transcriptome by performing a RNA-Seq experiment in this system. In order to
perform this experiment, we isolated organoids from the bigenic STOPPRMT6/MMTV-Cre, along with 2 control groups (STOP-PRMT6 and MMTV-Cre).
After 3 days in culture, we isolated the RNA from these cells and carried out the
RNA-SEq experiment (done by the Molecular Biology core of Science Park). In this
experiment, by applying the EdgeR analysis, we found a list of 127 differentially
regulated genes (mostly repressed in the bigenic mammary cells). With a more
stringent analysis (DESeq) the list of genes differentially regulated consists of 17
genes (Table 2), which have yet to be confirmed by qPCR. This experiment
suggests that PRMT6 indeed has a significant impact on gene expression.
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Gene

Fold difference between bigenic and
control

p value

Fxyd6

(log2ratio) (fold difference)
(-1.50402426) (0.352568561)

3.70E-06

Anpep

(-1.149596896) (0.450751158)

3.58E-05

Serpine2

(-0.875114644) (0.545210539)

6.77E-06

Ucp2

(-0.867534022) (0.548082881)

6.06E-06

Mgst1

(-0.814857227) (0.568464741)

2.97E-05

Adamts3

(-0.813866665) (0.568855186)

1.98E-05

4931406C07Rik

(-0.807541437) (0.571354701)

5.96E-07

(-0.688727492) (0.620400824)

2.01E-05

Prom1

(-0.678246736) (0.624924265)

8.21E-07

Mansc1

(-0.652710633) (0.636084073)

6.20E-06

Cdon

(-0.641127291)

(0.641211724)

4.68E-05

Man1c1

(-0.62168415)

(0.649911801)

4.67E-05

(-0.610811553) (0.654828241)

4.58E-05

(-0.593026224) (0.66295083)

3.18E-05

Lama3

(0.86487064)

4.88E-05

Abcc4

(0.886930746) (1.849237784)

5.41E-05

(1.058591443) (2.08289692)

3.61E-05

Add3

Tmem176a
Sort1

Nup210l

(1.821176374)

Table 2. List of genes differentially regulated in the mammary gland epithelial compartment of bigenic
STOP-PRMT6/MMTV-Cre mice. RNA was isolated from primary mammary epithelial cells of STOPPRMT6/MMTV-Cre, STOP-PRMT6 and MMTV-Cre mice. An RNA-Seq experiment was carried out and data were
analyzed by DESeq. In red are the repressed genes, in green the up-regulated genes when the bigenic group was
compared to the MMTV-Cre group. Data were reproducible when the bigenic group was compared to the STOPPRMT6 group.
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Chapter 6
Discussion and Future Directions
In this thesis I describe gain-of-function PRMT6 mouse models, which, to our knowledge,
are the first PRMT6 transgenic models to be generated. The phenotype of the mouse
model with ubiquitous PRMT6 stabilization (the ER*-PRMT6 model) is complex, with
activated PRMT6 likely impacting the methylation levels of many substrates. The
impacted substrates include dramatic changes in the histone code (which we have
observed), and possibly elevated methylation levels on non-histone substrates.
Chromatin is an active platform that mediates external and internal cellular signals into
dynamic changes in gene expression. Studies on high-order complexes during activation
of NF-

-regulated genes and the consequent impact on chromatin remodeling through

histone post-translational modification (PTM) have increased enormously in the past
decade and it has become clear that the NF-B transactivation is far more complex than
anticipated (26). A number of coactivators and mediators have been discovered to
regulate its transcriptional activity, indeed NF-B recruits a coactivator complex that has
striking similarities to that recruited by steroid nuclear receptors and the role of factors that
impact histone tail posttranslational modifications has become evident (31). Histone
arginine methylation by protein arginine methyltransferases has elicited a great deal of
interest due to increasing evidence that it regulates chromatin remodeling and gene
expression by providing docking sites for specific readers or effector molecules (4,24,83).
Herein I have shown that PRMT6 functions as a coactivator for NF-B-mediated gene
transcriptional activity. I arrived at this finding by observing an activated inflammatory
response in the transgenic ER*-PRMT6 mice. The specific involvement of PRMT6 in up-
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regulating inflammatory genes was confirmed by demonstrating that overexpression of
PRMT6 enhances NF-B transcriptional activity in cultured cell-based luciferase assays
and quantitative real-time PCR experiments. The activity of PRMT6 was clearly necessary
for the coactivator function. ChIP analysis demonstrated that PRMT6 was recruited to the
IL-6 promoter upon TNF-alpha stimulation. Moreover, overexpression of PRMT6 caused
RelA shuttling into the nucleus, which could justify, at least in part, the mechanism
underlying its coactivator function. Notably, PRMT6 has been found overexpressed in
many types of human cancers (39,55,56), therefore the facilitation of NF-B nuclear
shuttling could be an important mechanism contributing to NF-B-dependent gene
activation in cancer (84). It remains to be addressed if the increased nuclear RelA is the
result a direct shuttling due to PRMT6 binding to it or an indirect consequence of PRMT6
overexpression. Moreover, the increased PRMT6 localization at the IL-6 promoter upon
stimulation is indicative of regulatory signaling on PRMT6, possibly by post-translational
modification. One question that I sought to answer is: what is the role of arginine
methylation in PRMT6 coactivation of NF-B transcription? A number of PTMs on NF-B
subunits have been shown to affect its stability, function, subcellular localization and
binding to DNA (85). It has recently been published that PRMT5 (a type-II arginine
methyltransferase) methylates p65/RelA (86). This methylation event appears to increase
the ability of NF-B to bind to B elements and to drive gene expression. I investigated
the possibility of PRMT6 methylating RelA using in vitro methylation assays, but found
that this is not the case. Other modes of PRMT6 regulation could be through the
methylation of non-histone proteins that are associated with the NF-B complex or
through its ability to methylate histones. A recent publication has shown that PRMT6
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behaves like PRMT1 and CARM1, indeed it works as a secondary coactivator to
p160/SRC proteins (23). PRMT6 binds to the AD2 domain of SRC-1, and synergistically
coactivates ERα together with SRC-1. Therefore, PRMT6 can be considered a steroid
hormone receptor coactivator which interacts with SRC-1 to facilitate transcription. A likely
mechanism by which PRMT6 will function as a coactivator has recently come to light with
the finding that it methylates a site in the core of histone H3, H3R42me2a (25).
Importantly, the side chain of this arginine residue interacts with the DNA minor groove
and methylation of this site is proposed to sterically interfere with this interaction, as well
as remove a potential hydrogen bond donor, thus destabilizing the histone:DNA
interaction. Indeed, the incorporation of semisynthetic H3R42me2a into core histone
octamers, and use of these octamers in reconstituted chromatin for the generation of
chromatinized transcription template revealed this to be the case. Unfortunately, there are
currently no antibodies available to the H3R42me2a mark, so we are unable to test the
hypothesis that this histone methylation site is responsible for the coactivator functions of
PRMT6 in the context of nuclear receptor and NF-B signaling. PRMT6 has also been
reported to generate the active site H4R3me2a in vitro (9), therefore I sought to
investigate if this mark is also generated in vivo, which could account for a mechanism of
coactivation. I found that indeed not only PRMT6 overexpression causes global increase
of this mark in vivo, but also that this mark enriches at the IL-6 promoter upon TNF-alpha
stimulation in ChIP assays, concomitantly with PRMT6 recruitment, although the influence
of PRMT1 in this assays cannot be excluded. The impact of PRMT6 on H4R3 could also
explain the coactivator function towards nuclear receptors, but this hypothesis remains to
be tested.
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Due to lethality of the ER*-PRMT6 mouse model, I could not carry out cancer
studies with it, therefore a Cre-inducible mouse model was generated, allowing for tissuespecific overexpression of PRMT6. These mice were crossed to K5-Cre and MMTV-Cre
mice. The first experiment I set up was a skin carcinogenesis study utilizing the bigenic
STOP-PRMT6/K5-Cre mice, but did not observe a difference in tumorigenicity between
the experimental and control groups. This is likely due to the extreme focal nature of the
Flag-PRMT6 expression in the epidermis and hair follicles of the bigenic mice. According
to the cancer stem cells hypothesis for cancer development, the mechanism for tumor
initiation in two-stage carcinogenesis protocols that employ DMBA/TPA involves mutation
in the critical target Ha-ras gene of stem cells in the bulge region of hair follicles or basal
compartment of interfollicular epidermis (57). It is thus likely that none of the cells that
were targeted for Ha-ras mutation by the initiating agent DMBA was in fact overexpressing the exogenous Flag-PRMT6, therefore no difference in tumor susceptibility
was detected.
From the second cancer study I carried out (by performing a cross with p53+/mice) I did not detect increase tumorigenicity in the bigenic STOP-PRMT6/K5-Cre;p53+/mice compared to the controls, although an interesting phenomenon occurred, indeed the
females of the bigenic group showed signs of ongoing inflammatory response. This result
is in line with our observations of the ER*-PRMT6 model, which also showed an
inflammatory response upon PRMT6 stabilization. One question that arises is: why do
only the females showed this phenotype? Although there are numerous reports showing
negative cross-talk between ER and NF-B (70,87-90), these transcription factors have
also been shown to act synergistically (91-95) by forming a complex at the estrogen
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responsive elements (EREs) or NF-B responsive elements found in gene promoters. In
particular, the group of Stanculescu (95) has shown that E2 enhances TNF- alpha activity
on ≈15 % of TNF-alpha up-regulated genes. With this in mind, I can speculate that the
increased inflammatory response observed in the female mice in our study might be the
result of this synergism, given that PRMT6 is a coactivator for both these transcription
factors.
With the MMTV-Cre cross I found an interesting phenotype, indeed the bigenic
STOP-PRMT6/MMTV-Cre mice displayed a hyper-proliferative phenotype in the
mammary gland, which was detected by Ki-67 analysis (see Figure 25). Upon this
observation, I set-up an ageing study to investigate the possibility of increased
spontaneous mammary carcinogenesis in the bigenic STOP-PRMT6/ MMTV-Cre mice
compared to the controls. It is possible that the MMTV-Cre transgene per se is creating
the ideal conditions for PRMT6 to enhance cancer susceptibility. Peculiar phenotypes in
Cre-expressing mouse lines have been previously described. For example one of the
MMTV-Cre lines (the Line A) that were generated by the group of Hennighausen (82)
displays a lactation defect (96). For this reason, this line has been cryopreserved and is
not currently being used by any laboratory. The mice from the MMTV-Cre cross have
been aged until 12 months and analyses on the mammary tissue along with the controls
are underway. Some of the bigenic mice have developed large mammary tumors that are
currently being examined. If this study turns out to be inconclusive, it might be worth to
cross the STOP-PRMT6 mice with an oncogenic mouse model (i.e. MMTV-Myc mouse),
considering the hypothesis that PRMT6 may have a role in tumor promotion rather than
initiation. In the future, this type of mouse model could be valuable for the in vivo analysis

82

of small molecule PRMT inhibitors that are currently being developed both in academic
and pharma sets (97).
From the last experiment I carried out (RNA-Seq on primary mammary epithelial
cells) we found a list of genes that are potentially - directly or indirectly- regulated by
PRMT6. One gene that is up-regulated is miR-1943. MicroRNAs (miRNAs) have shown to
play important roles in physiological and malignant processes, including acute myeloid
leukemia (AML). The group of Humphries (98) applied the Illumina massively parallel
sequencing platform to carry out an in-depth analysis of the miRNA transcriptome in a
murine leukemia progression model and found miR-1943 among the most significantly upregulated miRs. It would be interesting to investigate if there is direct regulation of this
miR by PRMT6 at chromatin level, since PRMT6 is up-regulated in leukemia.
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